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Introduction: In vivo models have been required to demonstrate relative cardiac safety, but model sen-
sitivity has not been systematically investigated. Cross-species and human translation of repolarization delay,
assessed as QT/QTc prolongation, has not been compared employing common methodologies across multiple
species and sites. Therefore, the accurate translation of repolarization results within and between preclinical
species, and to man, remains problematic.Methods: Six pharmaceutical companies entered into an informal
consortium designed to collect high-resolution telemetered data in multiple species (dog; n = 34,
cynomolgus; n = 37, minipig; n = 12, marmoset; n = 14, guinea pig; n = 5, andman; n = 57). All animals
received vehicle and varying doses of moxiﬂoxacin (3–100 mg/kg, p.o.) with telemetered ECGs (≥500 Hz)
obtained for 20–24 h post-dose. Individual probabilistic QT–RR relationships were derived for each subject.
The rate-correction efﬁcacies of the individual (QTca) and generic correction formulae (Bazett, Fridericia,
and Van de Water) were objectively assessed as the mean squared slopes of the QTc–RR relationships. Nor-
malized moxiﬂoxacin QTca responses (Veh Δ%/μM) were derived for 1 h centered on the moxiﬂoxacin Tmax.
Results: All QT–RR ranges demonstrated probabilistic uncertainty; slopes varied distinctly by species where dog
and human exhibited the lowest QT rate-dependence, which was much steeper in the cynomolgus and guinea
pig. Incorporating probabilistic uncertainty, the normalized QTca-moxiﬂoxacin responses were similarly
conserved across all species, including man. Discussion: The current results provide the ﬁrst unambiguous ev-
idence that all preclinical in vivo repolarization assays, when accurately modeled and evaluated, yield results
that are consistent with the conservation of moxiﬂoxacin-induced QT prolongation across all common preclin-
ical species. Furthermore, these outcomes are directly transferable across all species including man. The consor-
tium results indicate that the implementation of standardizedQTc data presentation, QTc reference cycle lengths,
and rate-correction coefﬁcients can markedly improve the concordance of preclinical and clinical outcomes in
most preclinical species.© 2013 Elsevier Inc. All rights reserved.harles River Laboratories, 6995
9; fax: +1 775 682 2100.
refe),
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rights reserved.1. Introduction
Drug-induced prolongation of cardiac repolarization in some
instances increases the risk of potentially fatal arrhythmias, notably
Torsades de Pointes (TdP) and has been the subject of intensive
investigational and regulatory scrutiny during the past decade
(Redfern et al., 2003). TdP is an extremely rare but potentially lethal
adverse drug effect (Yap & Camm, 2003), where the rarity of TdP
led to the identiﬁcation and acceptance of QT prolongation as an
accessible, but imperfect, surrogate biomarker to gauge potential
repolarization risk in human studies Anonymous (2005a). Although
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prolongation in early-stage drug development (Honda, Kiyokawa,
Tabo, & Inoue, 2011; Tabo et al., 2010), these models cannot account
for possible systemic effects including the potential impact of metab-
olites, plasma protein binding, or physiological factors which elicit
changes in ECG parameters. As such, cardiac safety must still be eval-
uated in vivo (Anonymous, 2005a, 2005b). Prior to entry into man,
speciﬁc in vivo preclinical models have been required to evaluate
relative cardiac safety, but to date, systematic investigations of
model sensitivity to detect repolarization liabilities have not been
published. In particular, the cross-species and human translation of
the response elements of interest, the QT and RR intervals, have not
been characterized in parallel, employing common methodologies
across multiple species and investigational sites. Decision-making in
drug-development programs remains problematic due to the lack of
accurate translation of results within and between preclinical species,
and ultimately to man. Although QT effects are now typically charac-
terized in vivo followed by a Thorough QT (TQT) study in the clinic, the
ultimate goal is to obviate the TQT study by increasing the accuracy and
translational power of the relevant preclinical models (Leishman et al.,
2012). Today, one of the principal unanswered questions is whether the
primary animal readout, QT prolongation as currently assessed, is opti-
mal, and if not, can it be further optimized? Importantly, the ability of an
animal model to detect QT prolongation which translates to man does
not equate to the ability of animal QT prolongation to predict TdP in
man. Indeed, given the rarity of TdP within and between species, it is
unlikely that the later goal is feasible, at least for the foreseeable future.
The intrinsic rate-dependence of the QT interval and the require-
ment for rate-correction to enable QT interval comparisons between
observations has been exhaustively documented in many preclinical
species and in man. Multiple rate-correction approaches have been
implemented which purport to dissociate the effects of rate and yield
a more sensitive rate-corrected QT (QTc). However, as regulatory guid-
ances ICH S7B and E14 do not comment onwhich speciﬁc QT correction
methods are applicable for a given species, research institutions have
freely implemented various preclinical QT rate-correction methods
with varying degrees of precision and accuracy. Indeed, the most
commonly used QTc formulae are derived from human observations
and are not uniformly applicable across other species due to either a
drug effect and/or the intrinsic electrophysiology of each individual
and species (Batchvarov & Malik, 2002; King, Bailie, & Olivier, 2006).
While the rate-dependency of the human QT interval has been well-
characterized, to our knowledge there are no studies which have
systematically evaluated the utility of the generic rate-correction
methods (Bazett, 1920; Fridericia, 1920; Van de Water, Verheyen,
Xhonneux, & Reneman, 1989) across the typical preclinical animal
models (dog, cynomolgus monkey, minipig, marmoset, and guinea
pig) employing a common reference agent.
To date, the largest cross-species preclinical investigations remain
the PRODACT studies (Ando et al., 2005; Hashimoto, 2008; Miyazaki
et al., 2005; Toyoshima et al., 2005). However, the methodologies and
conclusions of these studies are now quite dated andwere not designed
to characterize the potential over and under rate-correction of the
generic QT methods that were employed. Nevertheless, the authors
demonstrated that the in vitro hERG, action potential (employing
isolated primary cardiomyocytes), and in vivo QT assays were predica-
tive of the human outcome. However, these studies lacked any compre-
hensive discussion of QT–RR relationships across species, and the
derivation, impact, and goals of QT rate-correction. All evaluated
species, including man, exhibit distinct, i.e. non-overlapping, QT–RR
domains. As such, the fundamental nature of the species-speciﬁc QT–
RR relationships and their interactions with the various rate-correction
methods must be clearly understood to effectively characterize the
sensitivity, accuracy, and translation of multiple diverse models.
The goal of any QT rate-correction procedure is to reduce QT mea-
surement error by effectively dissociating the effects of rate, yieldinga more stable measure, QTc. As such, QTc methods pertain only to
error reduction in the estimate of QT (QTc), and are intrinsically
unrelated to the direct quantiﬁcation of a given repolarization
response. QTc error has been extensively characterized in man and
robust methods, such as the mean squared slope (MSS) of the QTc–RR
relationship, affords an objective assessment of the efﬁcacy of any
given rate-correction procedure (Tornoe et al., 2011).
In addition to the well known rate-dependence of the QT interval,
accurate QT estimates are further confounded by marked rate-
independent variability where the raw QT for any given RR interval
is accurately represented only as the mean of a normally distributed
population (Holzgrefe, Cavero Gleason, Warner, et al., 2007), to the
exclusion of traditional sparse and discrete interval measurements.
The latter observation has a direct and potentially profound impact
on the derivation and output of all rate-correction formulae as the
models cannot exceed the accuracy of the underlying data. When
accurate raw QT estimates are employed in a rate-correction model,
the associated MSS approaches zero, providing an objective demon-
stration of rate-correction efﬁcacy, regardless of species. Indeed, it is
likely that a combination of the aforementioned sources of error was,
at least in part, responsible for the relatively weak preclinical–clinical
concordance of parallel repolarization assays recently reported by the
ILSI-HESI Pro Arrhythmia project (Anonymous, 2012).
Following the initial description of the probabilistic nature of the QT
interval in 2007 (Holzgrefe, Cavero, Gleason, Warner, et al., 2007), the
potential applicability of this ﬁnding across multiple sites and species
remained unclear. To more broadly address this matter, six companies
entered into an informal industry consortium designed to collect high
resolution telemetered data in multiple preclinical species across
geographically diverse sites. The primary consortium objectives were
to characterize species-speciﬁc QT and RR relationships, QT rate-
correction efﬁcacy, and the QT/QTc responses to vehicle and
moxiﬂoxacin treatments. Cross-species translation was assessed as
the consistency of the normalized QTc response to moxiﬂoxacin.
Human translation was established by benchmarking all preclinical
moxiﬂoxacin responses to those obtained in a previously disclosed
TQT study (Holzgrefe et al., 2012; Meyer, Ferber, Greig, & Holzgrefe,
2013).
The current report presents summary results for the primary
consortium endpoints obtained in dog (n = 34), cynomolgus mon-
key (n = 37), marmoset (n = 14), minipig (n = 12), guinea pig
(n = 5), and man (n = 57). The efﬁcacy of all QTc methods was
assessed by MSS, and represents the ﬁrst systematic preclinical appli-
cation of this methodology. Importantly, the current results for the
dog and cynomolgus monkey are derived from very large and diverse
populations acrossmultiple research sites,which convey unprecedented
descriptive and statistical power to the associated observations. A
detailed discussion of statistical theory in the context of QT analysis
and the detection of a signiﬁcant effect is presented to frame the overall
presentation.
2. The role of statistical modeling in QT assessment
The electrocardiogram and in particular the use of the duration of
the QT interval is an important safety parameter in drug development.
However, QT measurement is strongly dependent on the heart rate
prior to, and during the measurement interval (Batchvarov & Malik,
2002; Malik, Hnatkova, Novotny, & Schmidt, 2008; Malik, Hnatkova,
Sisakova, & Schmidt, 2008). To discern the effect on QT duration of
any controllable stimulus (e.g., drug or metabolite exposure), the QT
durations at different measurement time points must be corrected to
a reference heart rate, providing a rate-corrected “QTc” value corre-
sponding to each raw or uncorrected QT value. Technology that allows
high quality recording and storage of continuous ECG signals over
24 h and beyond has enabled substantially improved ECG data analysis.
In particular, it is nowpossible to use all measured beats over the course
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the QT intervals of each individual subject—preclinical animal or
human—for heart rate variation. The QTca method that is the focus of
this study has demonstrated its usefulness and validity to a virtual
certainty (Holzgrefe et al., 2012; Meyer et al., 2013).
This discussion presents the basic statistical principles underlying
the development and validation of individual heart rate corrected QT
measurements. Following some initial thoughts and considerations
on biological and statistical models it then discuses the validation of
measurement methods in the presence and in the absence of an
accepted gold standard. These principles are then applied to the
development of heart rate corrected QT measures, followed by a dis-
cussion of the statistical aspects of the QTca method (refs) and thus
provide a direct link to the cross-species QT/QTc results that comprise
the body of this report. The last section compares and contrasts differ-
ent individual QTc methods and addresses the limitations of any form
of heart rate correction in the presence of drug-induced changes in
heart rate, presenting some basic alternatives.
2.1. Principles and techniques of statistical modeling
Models are important tools for scientiﬁc research since they allow
focusing onmechanisms that, in a naturalistic setting, are embedded in
a complex environment thatmaymask the relationships of interest. Life
sciences use biological and clinical models. These models may be used
at different levels of complexity, such as ex vivo preparations, in vivo
systems, or clinical studies such as the ThoroughQT study. An important
feature of thesemodels is that they incorporate the essential features of
the phenomenon to be investigated, but are less complex than the
reality that they are meant to simulate. As a consequence, theoretical
explanations and practical predictions derived from models are never
without some uncertainty.
Apart from these naturalistic models, quantitative “in silico”
models also play a role in biology. Such an example is provided by
Quantitative Circulatory Physiology (QCP), a mathematical model of
integrative human physiology containing over 4000 variables (Abram,
Hodnett, Summers, Coleman, & Hester, 2007). The purpose of such
models can be prediction, education, and support in the understanding
of relationships in biology. These models distill the biological reality
of interest into amathematical structure. Again thesemodels are neces-
sarily simpliﬁcations of the biological reality and therefore the predic-
tions derived from these models have limitations.
Statistics are used in science as methods to infer relationships
between observations made. Whenever statistical methods are used
to interpret real world data, a suitable model is also required. Statistical
inference can be seen as the reconciliation of direct observations with
predictions. A fundamental concept in these models is independence
of observations. As an example, take three ECG measurements A, B,
and C performed under well-controlled and identical conditions. If B
and C aremeasured in the same subject, but at different times, knowing
the RR value of B inﬂuences expectations on the RR value of C much
more than A, the result of RR in a different subject. Therefore, the mea-
surements B and C are not independent. If, on the other hand, A, B, and C
represent measurements in three different people, one may assume
independence if there is no reason to believe that B and C are more
related than A and C.
Simple models assuming little more than independence underlie
many of the basic statistical tests, but more complex statistical models
may take into account details of the experimental design and/or some
biological relationships.
As mentioned above, statistical inference derives conclusions by
comparing the observed data with predictions derived from the
model used. In traditional frequentist terms, a conﬁdence interval
associated with a probability 1 − α for an unknown parameter is
the range of values for which outcomes at most “as extreme” as the
one observed have a probability of at least 1 − α given the statisticalmodel used. Broadly speaking, a conﬁdence interval gives the range of
values for an unknown “true” population-based model parameter
that are compatible with an individual set of original observations.
Since a ﬁnite set of measurements contains only a ﬁnite amount of
information, the associated inferences are also limited. As a conﬁ-
dence interval is wider with smaller sets of observations, it is not
surprising that with the same number of observations, the estimate of
a larger number of quantities can only be estimated with less precision.
On the other hand, a more complex but more realistic model can also
result in a more precise estimate if such a model enables the “explana-
tion” of some greater proportion of the observed variability. Conversely,
the use of an inappropriate model may lead to systematic errors in the
parameter estimates.
This notion can be reﬁned by deﬁning two concepts of variability:
• The random component of variation is the one that is manifested
when we repeatedly measure the same thing or repeat the same
experiment. A small random variability means that a measurement
method is reliable.
• The systematic difference between what we actually measure and
the quantity we want to measure is called bias. A method with little
bias is described as valid. However, validity can also be deﬁned as a
method that predicts with precision and accuracy— no false positives
or false negatives. Biased readoutmay exaggerate the numericalmag-
nitude of an effect, but this is unimportant if the readout accurately
predicts the existence of a TdP liability. The accurate enumeration of
the magnitude of a liability would be important if it were possible
to link a given change in QTc (ms) to an exact increase in TdP proba-
bility. Since this is not possible, bias in the present context, is not
directly relevant. This is important in terms of the factors inﬂuencing
both the model choice and subsequent analyses.
The choice of a statistical model should depend on the knowledge
of the subject matter and on the expectations that we have on the
behavior of the data. In an ideal world, where unlimited experimenta-
tion is possible, a complex statistical model would be preferred to
describe the associated experiment. However, if the data at hand
are limited, some of the model complexity may have to be sacriﬁced
in order to obtain less variable estimates of the parameters of interest.
In other words, a less complex model may be selected in order to gain
reliability. In this scenario, the reduction in random variation is
performed at the expense of the possible introduction of some sys-
tematic error or bias due to the oversimpliﬁcation of the model used.
2.2. How to validate a method
Reliability and validity are critical for the validation of a measure-
ment method. If the measurement can be compared against a gold
standard, i.e. an accepted measurement method that can serve as a
reference but may be too expensive to be used routinely, then both
the random variability and the systematic error can be estimated
directly. In such a case, ideally, the reference should be determined
as well as several replicates of the new method to be validated.
Assume that yij are the results of themethod to be validated for subjects
(or any other independent units where measurements are performed)
i = 1, …, n and the replicates j = 1, …, ki; let xi be the gold standard
measurement for subject i, againmeasuredwith some random variabil-
ity. In such a case themean squared deviation between the xi and the yij
is described as
Δ2 ¼ 1
n
∑
i
1
ki
∑
j
yij−xi
 2
:
This deviation can be decomposed into random components for x
and y and a systematic component, however this discussion is beyond
the scope of this overview.
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Fig. 1. Variability of individual heart rate correction in cynomolgus monkey. For 20
randomly selected individuals, the black squares present the QTca correction coefﬁcient
based on all available data. The open circles present individual correction coefﬁcients,
each based on a random 20% subset of the source data extracted without replacement.
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The random variability of a method can still be quantiﬁed as the mean
squared deviation
Δ2r ¼
1
n
∑
i
1
ki
∑
j
yij−xi
 2
around a common mean value,
xi ¼
1
ki
∑
k
yij
however, there is no direct way to infer any systematic error. There
may also be conceptual difﬁculties, in particular, if the quantity to be
estimated is not well deﬁned.
In such cases, it may be helpful to perform the samemeasurements
at different centers or laboratories. One can then investigate whether
the variability observed between centers can be explained by the ran-
dom variability observed within each of the centers, or if there seem
to be systematic differences between the centers that could indicate
that each of the centers indeed measures something slightly different.
In technical terms, such a meta-analysis can be performed by applying
some form of analysis of variancewith center as a factor. Assuming nor-
mality of the variable of interest, an F-test may be used to evaluate the
probability for the absence of a systematic center effect. Such a center
effectwould be an indicator against the validity of themethod under in-
vestigation. In some cases, the validity of themethod could be improved
by a better standardization of the measurement method.
2.3. The situation for QT and RR
The correction of QT for heart rate, originally described in humans
and later applied to other species as well, is a good example of the
advantages and limitations of statistical and quantitative biological
modeling. The initial work of Bazett and Fridericia was directed
towards reducing the variability observed in QT in patients (Bazett,
1920; Fridericia, 1920). Since these authors measured only a few
ECGs in each subject, they had to resort to universal and simple
“ﬁxed-coefﬁcient” correction formulae. These formulae provided a
substantial reduction in variability, but were not optimal. With the
advent of large clinical studies, it became possible to derive population-
speciﬁc corrections, such as the Framingham correction (Sagie, Larson,
Goldberg, Bengtson, & Levy, 1992). However, these corrections likewise
assume the same QT–RR relationship for all subjects, at least within
one study, and therefore ignore inter-subject variability. As became
clear over time, in order to adjust for individual differences in the
QT–RR relationship, an individual rate-correction must be used
(Batchvarov et al., 2002; Malik, Farbom, Batchvarov, Hnatkova, &
Camm, 2002). From a statistical perspective, rate-correction is used to
reduce the variability seen in QT measurements. The new variable,
QTc, is considered to vary less within a subject under physiological
conditions. Whether or not “the relationship between QT and HR can
be mathematically or statistically described by a formula” (Luo,
Michler, Johnston, & Macfarlane, 2004) need not be decided in this
perspective—it only matters that the new variable QTc is less variable,
i.e. more reliable, and represents a biologically valid concept. Obviously,
a ﬁxed coefﬁcient correction appropriate for the species can achieve
some reduction in variability.
The implementation of individual rate-corrections has become
attractive with the ready availability of digitized longitudinal data
from each subject, as is typically the case in current TQT studies and
in the current preclinical datasets. It has been repeatedly stressed
(e.g. ICH E14), that this concept can only be used if (1) a sufﬁcient
number of ECGs under baseline conditions are available and (2) the
range of heart rates of these ECGs spans the range expected under ex-
perimental conditions (Malik, Hnatkova, & Batchvarov, 2004; Malik,Hnatkova, Kowalski, Keirns, & van Gelderen, 2012; Malik, Hnatkova,
Schmidt, & Smetana, 2008). In such cases, an individual correction
may further reduce the variability of QTc. If only the values obtained
under tightly controlled baseline conditions of a TQT study are avail-
able, the second condition may not be met. With the advent of high
quality Holter monitoring, options including either using all beats
from a 24 h baseline recording, or using all beats that meet some
quality criterion became an option. With this kind of methodology,
the two limitations of individual corrections can be overcome. The
number of beats available per subject is in the range of 100,000 for
humans and in a similar range for other nonclinical species. More-
over, as the heart rates encountered typically span the physiological
range, extrapolation is rarely needed.
Wang, Pan, and Balch have shown that as one progresses from a
ﬁxed correction like Fridericia's to a study-speciﬁc correction, and
further, to an individual correction, the systematic error is reduced
while the random variability increases with the number of additional
parameters that need to be estimated (Wang, Pan, & Balch, 2008). The
systematic error of Bazett's formula has been described repeatedly—
usually as an over-correction, i.e. QTcB for a long RR is excessively short-
ened with respect to the raw QT, while for a short RR, QTcB is too long.
The systematic error for Fridericia's correction is less evident and appar-
ent only if data from each subject are inspected individually.
The variability of a study-speciﬁc correction manifests itself in the
random variability of the estimates for the rate-correction coefﬁcients,
and this variability is even more pronounced when the determination
of separate correction coefﬁcients for each individual subject is consid-
ered as the latter are based on smaller datasets. This is illustrated in
Fig. 1 where, apart from a correction coefﬁcient derived from all data,
values were also derived based on 5 random subsamples of all beats.
The variability of these values illustrates the random variability of the
individually determined correction coefﬁcients, since all values are
representative of the same time period. In other words, while the
rate-correction coefﬁcient is ﬁxed and does not have any random
variation for Fridericia's correction, the associated random variability
may be considerable for individual rate-corrections which are derived
from, and applied to, an individual subject. Individual rate-correction
variability may be further exacerbated if the coefﬁcients are based on
limited numbers of ECGs encompassing a narrow range of heart rates.
In this perspective, and stipulating that the goal of heart rate-
correction is to reduce variability, the choice of a model for rate-
correction, such as linear, parabolic (i.e. of the form QTc = QT /RRβ),
hyperbolic (i.e. linear in heart rate) is reduced to a fundamental
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Fig. 2. Correction coefﬁcients for 60 participants in a 3 period crossover TQT study.
The correction factors for a parabolic correction were determined from the 24 h Holter
recording at baseline for the periods 2 and 3. The dashed line is the one of equal
coefﬁcients in both periods.
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variability under physiological conditions?
As discussed previously, it is difﬁcult to validate a method in the ab-
sence of a gold standard. In the case of QTc, however, we have some
means for a partial assessment of validity. Since the concept of QTc is
to obtain a measure of QT that is independent of RR, a valid correction
should, indeed, remove the variability due to this inﬂuence under nor-
mal conditions. Tornoe et al. describe several methods to assess the
error of rate-correction methods (Tornoe et al., 2011). One of these
uses the squared slope of a linear regression of QTc values on RR.
More speciﬁcally, the mean across individuals over the squared slopes
is used. If a correction works well, this slope should be close to zero.
To obtain a result that can be generalized beyond the original dataset,
the slopes used for validation should be derived from data distinct
from those used to derive the correction itself.Moreover, if the potential
inﬂuence of a drug is of interest, validation must be performed on data
obtained in a drug-free condition. If two distinct sets of QT/RR pairs
under “baseline” conditions are available, such as a screening ECG and
a baseline ECG, or baseline ECGs for each individual period of a cross-
over study, one of them can be used to determine individual and
study speciﬁc corrections, and the other can then be used for validation,
i.e. to determine the linear regression of QTc on RR and calculate the
mean squared slope (MSS). The mean squared slopes measure random
variability e.g. that caused by the random error of the individual correc-
tion coefﬁcients, as well as part of the systematic error, which may be
caused by the selection of an inappropriate correctionmodel. In the cur-
rent studies,MSSwas derived for each species fromoff-drug continuous
data (18–24 h) for the raw QT, Van de Water (QTcV) (Van de Water
et al., 1989), Fridericia (QTcF) (Fridericia, 1920), Bazett (QTcB)
(Bazett, 1920), and individual probabilistic (QTca) (Holzgrefe, Cavero,
Buchanan, Gill, & Durham, 2007) rate-corrections.
Benatar and Deraene showed that the QT–RR relationship may vary
with the condition under which the ECG is recorded (Benatar &
Decraene, 2001). On the other hand, Batchvarov et al. have convincingly
shown that the inter-individual variability of the coefﬁcients describing
the QT–RR relationship outweighs the changes seen under similar
conditions within a subject over time (Batchvarov et al., 2002). This,
however, does not mean that this relationship is completely stable
over time. In a three-period crossover Thorough QT study based on 64
subjects (iCardiac technologies, Rochester, unpublished results), rate-
correction coefﬁcients based on 24 h recordings taken separately from
the baselines of period 2 and period 3 were compared. For a parabolic
(log–log-linear) correction, the result is shown in Fig. 2. A regression
of the coefﬁcients obtained in period 3 on those obtained in period 2
resulted in an R2 of 0.46, while a hyperbolic correction (i.e. linear in
heart rate) yielded an R2 of 0.67. These observations can in part be
due to random variability of the estimate of the correction coefﬁcients,
but may indicate that in man only a modest stability of the QT–RR rela-
tionship can be expected under similar conditions. They are consistent
with similar analyses performed in other TQT studies. In the clinical
TQT study, these observations suggest that contemporaneous individual
rate-correction coefﬁcients be employed wherever possible to assure
maximum accuracy. In the current preclinical studies this was regarded
as a best practice, but reproducibility of QT–RR relationships is also a
function of the interval measurement methodology and the intrinsic
rate-dependence within a given species. See Section 10 for species-
speciﬁc details.
2.4. Statistical discussion of QTca methodology
Apart from the statistical requirement to have a wide range of
QT–RR pairs to determine the individual rate-correction coefﬁcients,
the reality that the QT, and therefore the QT–RR relationship, is
inﬂuenced by many factors must be considered. To obtain a represen-
tative rate-correction, an obvious method is to use all valid beats
of a prolonged recording for the determination of the correctioncoefﬁcient. This recording should include different states of the circa-
dian period and therefore should preferably span 18–24 h.
Conceptually, the simplest way to obtain a correction based on a
24 h recording is to ﬁt a suitable model, such as a parabolic, to all
QT–RR pairs. A parabolic model is one that is linear in log QT and
log RR. In other words, a model of the form
logQT ¼ aþ β logRR þ ε
is ﬁtted to the data. From this model a prediction of QT (QTc) for a
reference value of RR which typically varies by species (i.e. 1000, 750,
and 500 ms for human, dog, and cynomolgus monkey, respectively)
can be derived by the expression
logQTp ¼ aþ β logRRref
which translates to
QTp ¼ QTc ¼
QT
RR=RRrefð Þβ
:
Of course, data quality control and removal of low quality beats
should precede the derivation of an individual rate-correction. In
practice this has typically been accomplished by the application of
post hoc ﬁlters to the replayed data where the ﬁlters are broadly set
by species to exclude interval values which lie outside of the
established electrophysiological norms. For example, with the
cynomolgus monkey the ECG ﬁlters would be set to exclude beats
where the RR was 225b>1000 ms, PR was 60b>140 ms, QRS was
20b>70 ms and raw QT was 140b>350 ms. For beats where any
interval lies outside of the normative values (speciﬁed within a
study protocol), all associated interval data (PR, RR, QRS, and raw
QT) would be excluded from further analysis. In the current study,
the application of post hoc ECG ﬁlters typically resulted the exclusion
of b2% of the replayed data. Importantly, the incidence of ﬁltered
values has been shown to be random, and uniformly distributed
over time (Holzgrefe, Tichenor, Kaiser, & Meyer, 2013). Prior to the
introduction and validation of ECG pattern recognition software,
ﬁlters had to be employed without direct waveform veriﬁcation due
to the size and temporal constraints associated with the analysis of
24 h beat-to-beat datasets. Pattern recognition analysis compares
each waveform to a user deﬁned template, enabling the beat-to-beat
user veriﬁcation of all waveforms (Meyer et al., 2013).
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Fig. 3.Mean values in the RR–QT plane. Values were measured before and at 1, 2, 3, 4,
5, 6, 8, 10, 12, 14, 16, 18, 20, and 22 h after dosing at steady state. Each data point
represents the average of up to 27 subjects for RR and QT. Points are connected by
arrows in the sense of progressing time. The triangles and thin arrows represent the
data under placebo, while the squares with bold lines represent values obtained
under the test drug. The dotted lines represent lines of equal QTcF (values indicated
in the center of the ﬁgure). Comparing the traces for placebo and active drug, the
bradycardic effect of the drug becomes obvious. While under placebo, there seems to
be a well-correlated linear relationship between RR and QT, albeit different from that
suggested by the Fridericia correction, this is no longer the case with the active drug.
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Fig. 4. Effects of nitroprusside in the dog. QT–RR pairs obtained under baseline condition
(triangles) contrasted with those obtained from 3 to 4 min after the infusion of
nitroprusside (circles). This two dimensional presentation allows a clear visualization of
both the RR and QT effects and a comparison to the reference at baseline.
Adapted from Fossa et al. (2005).
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technical problems, because a regression based on 70,000 to
100,000 pairs of values may not be feasible with some software. To
facilitate management of these large datasets, the authors of the QTca
method employed a binning step before the regression (Holzgrefe,
Cavero, & Gleason, et al., 2007; Holzgrefe et al., 2012). Performing the
regression on the centroids of all beats in a bin of a certain RR width
(typically 10 ms) affords the opportunity to exclude bins that contain
only a few beats and therefore most likely represent extreme values.
On the other hand, since each bin is weighted equally in the regression,
individual beats in a bin with a small number of beats receive more
weight than those in a highly populated bin.
From a statistical perspective, one would not expect big differ-
ences between a direct regression and one based on the means of
adequately sampled bins, the main difference being the possible
effect of differential weighting of individual beats (Holzgrefe et al.,
2012). Separate investigations have addressed this issue and have
described rate-independent raw QT variability where a minimum of
250 beats is typically required to accurately estimate the raw QT asso-
ciated to any given RR interval (Holzgrefe, Cavero, Buchanan, et al.,
2007; Holzgrefe, Cavero, Gleason, Warner, et al., 2007). Based upon
these observations, the current report excluded all bins containing
b250 beats from the QT/RR regression analysis.
2.5. Drug-induced changes in heart rate
Historically, the effects of changes in heart rate on the QT interval
have been treated as a nuisance that could not be controlled and that
the associatedQT variabilitywas best taken into account during the anal-
ysis by constructing a parameter that minimized dependency on heart
rate (QTc). However, if we are studying drugs or other maneuvers that
have a direct effect on heart rate, this approach may become problem-
atic. Conceptually, QTc was introduced to reduce that part of QT vari-
ability that was related to changes in RR and assumes that changes in
RR are not of primary interest. However, if a drug inﬂuences both QT
and RR, these assumptions need to be challenged. While drug-induced
changes in RR should not be neglected, it may or may not be the case
that, although the drug inﬂuences both QT and RR, it leaves the relation-
ship between the two unchanged. Furthermore, a variable like the pre-
dicted QT value at a speciﬁed heart rate such as 60 bpm may not be
appropriate, since the heart rate observed with drug may not corre-
spond to the off-drug heart rate typically seen under similar conditions.
If a drug inﬂuences both QT and RR, it seems appropriate to visualize
the effect in a two-dimensional RR–QT plane. Lines of equal QTc for a
given correction formula can be plotted in this plane. This has been
done for QTcF in Fig. 3 which displays the mean values (n = 27)
obtained in a TQT study which investigated the effect of a bradycardic
drug in steady state, i.e. after multiple dosing, over 22 h (squares) and
for the corresponding values under placebo (triangles). Times after
administration of the last dose have been added to each point to allow
a time-matched comparison between the treatments. Apart from
looking at the changes in RR (horizontal shift), and QT (vertical shift),
changes in QTc are represented by the count of the number of lines of
equal QTc crossed. The change parallel to these lines corresponds to
shifts that do not affect QTc at all. Clearly, under placebo, there seems
to be a rather narrow relationship between QT and RR, although it
does not precisely follow the lines of constant QTcF. With drug, both
the bradycardic effect and the dispersion of the QT–RR relationship
are evident, suggesting that although RR prolongation is accompanied
by a QT prolongation, the latter does not follow the former to the extent
suggested by the relationship seen under placebo conditions. Overall,
QTcF is shortened but since the RR ranges with placebo and active
drug do not overlap, any comparison with respect to a form of QTc is
an extrapolation and has some element of speculation.
This approach has been employed to depict the simultaneous QT
and RR effects observed in dogs during the intravenous infusion ofnitroprusside (6 μg/kg/min for 20 min) (Fossa et al., 2005). Fig. 4
depicts the changes in RR and QT from 3 to 4 min after the start of a
nitroprusside infusion on the background of parallel data obtained
with vehicle.
Although an RR–QT plane yields impressive illustrations of possible
drug effects, a quantitative treatment of this type of data is not trivial.
Even simple measures, such as change from baseline, become problem-
atic if the change is not independent of the baseline value. For a statisti-
cal treatment, this approach requires the use of multivariate statistics
which preferably should be nonparametric. A simple interpretation of
results in more than one-dimensional space is hampered by the fact
that there is no intuitive natural ordering (e.g. by size) of the values in
such a space.
3. Methods
3.1. Global animal care and use statements
Care of the animals and the protocol designs presented in this
consortium report complied with all applicable local, national, and
Table 1
Species-speciﬁc RR reference cycle lengths. Reference cycle lengths within the normal
physiological range were employed for all within species QTc calculations (see text).
Species RR ref (ms) Heart Rate (bpm)
Human 1000 60
Dog 750 80
Minipig 750 80
Cynomolgus 500 120
Marmoset 400 150
Guinea pig 260 230
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Directive 86/609/EEC European Convention for the Protection of
Vertebrate Animals used for Experimental andOther Scientiﬁc Purposes
and the Animals (Scientiﬁc Procedure) Act 86 in the United Kingdom
and the USDA Animal Welfare Act (9 CFR, Parts 1, 2 and 3) and as
described in the Guide for the Care and Use of Laboratory Animals
Guide published by the US National Research Council (8th Edition,
revised 2010). All Protocols were approved by the appropriate Institu-
tional Animal Care and Use Committees. Animal care and use methods
are presented in the site/species-speciﬁc Appendices.
3.2. Site designations
Consortium sites are presented in single-blind fashion and are
designated as sites A–G. The same site designation is retained where
multiple species are employed by a single site.
3.3. Individual QT–RR relationships and QT rate-corrections
Raw data from the participating sites were imported into a custom
automated spreadsheet (Microsoft Excel, Redmond, Washington) for
further analysis. Corrected QT values were derived for each subject
and test session based on raw QT and RR data, and summarized in
successive 5 min increments. QT rate-corrections included van de
Water (QTcV), Fridericia (QTcF), Bazett (QTcB) and individual probabi-
listic (QTca) methods. Generic rate-corrections employed an RR
reference rate of 1000 ms, consistentwith their original intent and sub-
sequent use. For QTca, a species-speciﬁc RR reference cycle length was
employed as subsequently described. An experimental timeline was
added to each dataset (5 min resolution) such that zero (0) time
corresponded to the time of dosing. Experimental data were then
queried by subject and dose for 5 min time bins with ≥250 ECG cycles
and were presented as conventional x–y plots to illustrate time-
dependent changes over the observation period.
Individual probabilistic (QTca) rate-corrections were derived as
previously described (Holzgrefe et al., 2012). Brieﬂy, raw QT and RR
values from the vehicle data collection for each subjectwere individually
grouped into ascending 10 ms RR bins. Themean RR and raw QT values
for each bin containing ≥250 complexes were log-transformed and
the relationship of QT to RR was obtained as the slope (β) of the
log-transformed QT and RR mean values according to the following
regression model.
log QTrawð Þ ¼ β⋅ log RRrawð Þ þα: ð1Þ
After determination of the individual β values, Eq. (2) was applied
to each raw QT value to derive the distribution-based rate-corrected
QT (QTca)
QTca ¼ QTraw= RRraw=RRrefð Þβ ð2Þ
where QTraw = uncorrected raw QT interval in ms, RRraw = RR
interval in ms associated with the raw QT, and RRref = reference
heart rate, set to a species-speciﬁc RR interval that reﬂected a prevalent
resting heart rate achieved by all test animals (Section 3.3.2). Following
application of Eq. (2) to the raw data, all ECG values were expressed as
consecutive 5 min mean values where a minimum of 250 valid beats
were required for inclusion within each 5 min period. The latter steps
were necessary to adjust for rate-independent QT variability and to
quench the possible effects of QT hysteresis (Holzgrefe, Cavero,
Gleason, Warner, et al., 2007). To ensure the reliability of individual QT
rate-correction factors,β valueswith an associatedR2 b 0.9weredeemed
unacceptable and excluded from analysis (see Appendix Section 1.3 for
detailed QTca method application).
Species-speciﬁc QT–RR cloud plots were prepared from the vehicle
QT–RR pairs constrained to the associated 95% conﬁdence intervals. Tofacilitate comparisons of cloud densities across species where the
number of subjects and heart rate varied, all QT–RR vehicle data were
randomly sampled to yield ~4K data pairs for inclusion in each species
cloud plot with the exception of the guinea pig (1.3K pairs). To facilitate
direct comparisons, all cloud plots span an absolute QT range of 300 ms.
For reference, the canine cloud is presented in all graphs.
All statistical procedures were performed with Analyse-It Software
Ltd. (ver. 1.71), Leeds, England, UK. In all cases, a p value≤0.05was con-
sidered statistically signiﬁcant. Where applicable, data are presented as
the mean ± SEM.
3.3.1. QTca AUC methods
For each subject, the moxiﬂoxacin-associated change in QTca was
expressed as the % change from the time-matched individual vehicle
treatment. The results were then normalized for exposure by dividing
the % change in QTca (Δ%) by the exposure to obtain a response
variable expressed asΔ%/μM. In order to directly compare effects across
species where moxiﬂoxacin effects on QTca ranged from b3 h (guinea
pig) to >24 h (minipig), a QTca AUC (Gibaldi & Perrier, 1982) was
derived for each subject for 1 h centered on the species-speciﬁc
moxiﬂoxacin Tmax employing a subinterval width of 0.08334 h
(5 min). Moxiﬂoxacin plasma exposures per mg of administered
compound were linear across all doses and species (data not shown)
thus enabling all doses to be expressed on a common normalized
scale without further dose adjustment. This approach to exposure–
response normalization for cross-species comparison is supported by
understanding that moxiﬂoxacin prolongs QT interval by direct interac-
tion with the hERG channel, related to simultaneous plasma drug
concentration.
3.3.2. RR reference cycle lengths
The original QTc rate-correction formulaewere derived fromhuman
data (Bazett, 1920; Fridericia, 1920) which normalized the raw QT to a
reference cycle length of 1 s (1000 ms). For purposes of veriﬁcation, the
RR reference cycle length should correspond to a cycle length that is
within the normal physiological range for the species in question so
that the associated QTc intervals may be directed veriﬁed from in
vivo observations. Physiologically appropriate RR reference cycle
lengths have been previously suggested for the marmoset (400 ms)
(Tabo et al., 2008), cynomolgus monkey (500 ms) (Holzgrefe, Cavero,
Buchanan, et al., 2007), and minipig (830 to 1000 ms (Kano et al.,
2005; Markert et al., 2009). Many large pharma and CROs have
employed a canine RRref of 700–750 ms for internal and regulatory
use (data not shown). To enable direct in vivo veriﬁcation of all QTca
derivations, the consortium adopted species-speciﬁc RR reference
cycle lengths chosen to represent mid-range physiological cycle lengths
that were achieved by all subjects within a given species (Table 1).
3.4. QT/QTc–RR slope analysis
An ideal rate correction produces a QTc/RR proﬁle with a slope of
zero, indicating that, in the absence of drug, QTc is corrected to the raw
QT value associated to the RR reference value, conﬁrming complete dis-
sociation of the effects of rate. Accordingly, the individual QTc/RR slopes
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rate-correction method employing a LINEST function (Microsoft Excel,
Redmond, WA) to evaluate rate-correction performance.
3.5. Mean squared slope (MSS)
As previously discussed, a critical component of any QT analysis is to
characterize the adequacy of the rate-correction method(s) prior to
performing any central tendency or PK–PD analysis. For the current
datasets, individual linear QTc–RR regressions were performed for all
vehicle treatments and the means of the squared QTc–RR slopes (MSS)
were derived for each QTc method. The mean squared slopes measure
random variability e.g. random measurement error of the individual
correction coefﬁcients, as well as part of the systematic error which
may be caused by the selection of an inappropriate rate-correction
model. As such, the adequacy of any given rate-correction to dissociate
the effects of heart rate is directly reﬂected by the MSS, where this
value approaches zero with an ideal rate-correction (Tornoe et al.,
2011). For comparison, MSS was also derived for the raw QT.
3.6. Impact of heart rate changes on QT/QTc
To examine the comparative effects of changes in heart rate on QTc
rate-correction methods, a QT reference value (QTref) was established
for each species and for each method. Within each species, individual
QT/QTc–RR regressions were obtained from the vehicle treatment
data employing a LINEST function (Microsoft Excel, Redmond, WA).
QTref was then obtained as the predicted QT at the appropriate refer-
ence cycle length RRref employing a linear regression model (3) of the
means of the individual regression values for each species
QTref ¼ θ  RRref þα ð3Þ
where θ = regression slope, RRref = reference cycle length, and α =
regression intercept. RRref was then varied by ±20% for each species
and for each rate-correction method. The changes in the associated
QTref were then expressed as the % change from the QTref obtained at
the normalization cycle length (ΔQTref) for each QTc method (QTca =
probabilistic individual, QTcV = Van de water, QTcF = Fridericia,
QTcB = Bazett). For comparison, a parallel analysis was performed
for the raw QT data employing the appropriate species-speciﬁc RRref
normalization cycle length (Table 1) for the raw QTref derivation.
3.7. Site concordance
The potential for within-species systematic differences between
test sites was evaluated for the individual-animal rate-correction
coefﬁcients (β) and the response to moxiﬂoxacin presented as ΔQTca
(%)/μM moxiﬂoxacin plasma concentration (Cmax). For β an analysis
of variance and F tests were performed with β as a dependent variable
and test site as an independent variable. Since one of the sites tested
only a single moxiﬂoxacin dose while other sites used multiple doses
per animal, this simple analysis (with dose as additional factor and sub-
ject as random effect) was not possible for ΔQTca, and a two-step anal-
ysis was used. Speciﬁcally, a common dose-dependency was estimated
in a ﬁrst regression step (mixed effects model with subject as random
effect), and the residuals from this analysis were then subjected to a
second analysis of variance (mixed effects model) taking into account
the site as only a ﬁxed effect. The potential impact of sex, age, and
body weight was also assessed. Potential outlier sites were identiﬁed
using 95% conﬁdence intervals around the unweighted average values
across sites using a model with dose and site as factors (but no interac-
tion). See Appendix Section 2.2 for analysis details and results.4. Dog
4.1. Introduction
The beagle dog is the most commonly used non-rodent species for
nonclinical toxicology testing (Guth, 2007; Olson et al., 2000; Pollard
et al., 2010). It is purpose-bred and readily available, is less expensive
and easier to handle than nonhuman primates or minipigs, is amenable
tomultiple routes of drug administration, and has pharmacokinetic sim-
ilarities to humans to support human dose and exposure projections
(Martignoni, Groothuis, & de Kanter, 2006). Moreover, the dog has a
high positive concordance among preclinical species for predicting
human toxicity (Olson et al., 2000). These factors, and an extensive
historical data base, are expected to make the dog a mainstay in the
industry for the foreseeable future. From a cardiovascular (CV) perspec-
tive, the dog is themost commonly used non-rodent species for preclin-
ical testing and is considered by some to be themost appropriate species
for this purpose (Friedrichs, Patmore, & Bass, 2005; Gralinski, 2003;
Greaves, 1998; Leishman et al., 2012; Lindgren et al., 2008; Markert,
Shen, Trautmann, & Guth, 2011). This prevalence is based on features
amenable for CV testing and on the practical advantage of using the
same non-rodent species in toxicology and CV testing within a drug de-
velopment program. Canine cardiac ion channel activity and distribu-
tion are similar to humans (Gralinski, 2003; Wymore et al., 1997), and
responses in the dog are consistent with clinical outcomes for positive
and negative agents (Hanson et al., 2006;Miyazaki et al., 2005). Another
positive feature of the dog is its size, which supports surgical instrumen-
tation for cardiovascular telemetry studies (Eckardt, Haverkamp,
Borggrefe, & Breithardt, 1998; Guth, 2007), and intra-thoracic placement
of ECG leads that generate high amplitude ECG tracings largely devoid of
movement artifacts (Holzgrefe, Cavero, Gleason, Warner, et al., 2007).
Due to the pronounced electrophysiological inﬂuence of high
vagal tone (Boucher, Dubray, & Duchene-Marullaz, 1986; Little, Julu,
Hansen, & Reid, 2005), canine QT rate-dependence is less pronounced
than the other species examined herein. Nevertheless, eliminating
the effects of heart rate remains necessary when evaluating potential
changes in the canine QT interval. With the dog, approaches in this area
have evolved since the ﬁrst population-based QT rate-corrections were
introduced (Bazett, 1920; Fridericia, 1920). In 1989 the ﬁrst canine-
speciﬁc QT rate-correction was proposed (Van de Water et al., 1989).
More recently, issuance of the ICH S7B guidance for CV safety testing
(Anon) fostered rapid and sustained growth of conscious instrumented
animal models that provide continuous QT and RR data amenable
to the generation of subject-speciﬁc QT rate correction formulae
(Champeroux et al., 2009; Fossa, DePasquale, Raunig, Avery, &
Leishman, 2002; Holzgrefe, Cavero, Gleason, Warner, et al., 2007;
Matsunaga et al., 1997; Miyazaki & Tagawa, 2002; Raunig, Depasquale,
Huang, Winslow, & Fossa, 2001; Spence, Soper, Hoe, & Coleman, 1998;
Watanabe & Miyazaki, 2006). There is now general recognition within
the industry that rate-corrections based on the QT–RR relationship for
individual subjects are the most appropriate whenever a heart rate
correction is employed (Leishman et al., 2012). The individual ani-
mal rate-correction used herein (QTca) takes the method a step fur-
ther and accounts for the impact of hysteresis and intrinsic rate-
independent QT variability by estimating QT as a probabilistic variable
from the normal population of values associated with any correspond-
ing RR interval (Holzgrefe, Cavero, Gleason, Warner, et al., 2007).
In the current study, raw QT and RR data were provided by 5 sites
following vehicle and treatment with moxiﬂoxacin at 3, 10, 30, and/or
90 mg/kg. All ECG data were analyzed at the respective sites as sub-
sequently described and provided to the consortium at a default
resolution of 5 min. The response to moxiﬂoxacin is described for
QT corrected for heart rate using QTca. The performance of QTca
and three commonly used generic rate-corrections (QTcB, QTcF, QTcV)
also are described for data generated following vehicle (control)
administration.
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Summary data for 34 dogs (10.50 ± 1.51 kg, 21.4 ± 9.1 months,
21 male, 13 female) at 5 sites (A, B, C, E, and G) are presented. See
Appendix Section 2.1.1 for site-speciﬁc housing, data acquisition,
and treatment details.
4.3. Results
4.3.1. QT–RR analysis
4.3.1.1. QT–RR distributions. Representative QT and RR pairs after vehi-
cle treatment for the 34 dogs are presented in Fig. 5. RR and QT pop-
ulations were normally distributed and under control conditions
(2.5%b>97.5% quantiles) ranged from 440 to 1193 ms for RR (50 to
136 bpm) and from 174 to 283 ms for raw QT.
4.3.1.2. Site concordance. The potential for systematic differences
between test sites was evaluated for the individual-animal correction
coefﬁcients (β) and the response to moxiﬂoxacin presented as ΔQTca
(%)/μM moxiﬂoxacin plasma concentration (Cmax). The site speciﬁc
mean values for βwere generally equally distributed around a common
mean and both extreme values (sites B and E) differed signiﬁcantly
from the common average. For ΔQTca (%)/μM, there was no strong
indication for a site effect, though site B tended to be different from
the mean (p = 0.071). Follow-up outlier analysis supported this
conclusion. For β and ΔQTca (%)/μM; sex, age, and body weight did
not contribute to site variability (see Appendix Section 2.2 for details).
4.3.1.3. QT/QTc–RR slope analysis. The individual-animal QT/QTc–RR
slopes indicated that QTca performed optimally, and both QTcV and
QTcF performed acceptably well (Fig. 9). For the dog, QTcB resulted
in a consistent over-correction and was inappropriate in this species.
It also is apparent from Fig. 9 that QTca minimized inter-animal vari-
ability in the QTca–RR slopes, whereas inter-animal variability for the
generic corrections was similar to or increased relative to raw QT–RR.
4.3.1.4. Canine MSS summary. To further evaluate the performance of
the QT rate-corrections, individual linear QTc–RR regressions were
performed for all vehicle treatments and the means of the squared QTc–
RR slopes (MSS) were derived (Fig. 10). Consistent with QTc–RR slopes
(Fig. 9), the individual QTca correction was the most efﬁcacious method
(0.0001 ± 0.0002). For the generic rate-corrections, QTcV and QTcF
performed acceptablywellwhereasQTcBwas unsuited for use in the dog.
4.3.1.5. Impact of heart rate changes on QT/QTc. To examine the practi-
cal impact of rate-correction performance, QTc was derived for each
correction method at RR intervals associated with 20% increases and
decreases from a 750 ms reference value (Fig. 11, Table 2). The raw
QT exhibited the expected rate-dependent changes which were effec-
tively dissociated by the application of QTca, QTcV, and QTcF correc-
tions. In contrast, QTcB over-corrected the raw QT as RR shortened,
and under-corrected as RR was prolonged, demonstrating that this
method is unsuited for use in the dog.
4.3.2. Moxiﬂoxacin
4.3.2.1. Exposure and pharmacokinetics. Pharmacokinetic evaluations
were not systematically performed, but the available moxiﬂoxacin
plasma-concentration data from these studies were consistent with
cited moxiﬂoxacin toxicokinetic proﬁles, and these cited proﬁles were
used for PK–PD modeling (Chaves et al., 2007; Chen et al., 2005).
Based on these observations, single doses of 10, 30, and 90 mg/kg
were projected to yield moxiﬂoxacin exposures (Cmax) of 3.1, 8.6,
and 19.8 μg/mL4.3.2.2. QT and RR effects. Time-course proﬁles for RR, rawQT, and QTca
after vehicle andmoxiﬂoxacin administration are presented in Figs. 6–8
for 4 sites which employedmorning dosing (A, B, E, and G). A single site
employed afternoon dosing (C) and is not included in the graphic sum-
mary due to pronounced diurnal QT and RR differences relative to the
time of dosing. However, data for site C demonstrated moxiﬂoxacin-
induced increases in QTca relative to time-matched controls, consistent
with ﬁndings at the other sites. Expected decreases in QT and RR
occurred during animal handling for dosing and toxicokinetic sampling.
Moxiﬂoxacin was associated with a decrease in RR (150–200 ms) at
90 mg/kg, but otherwise had no noteworthy effect on heart rate. The
raw QT was increased moderately at 10 and 30 mg/kg and markedly
at 90 mg/kg, with peak effects 1.5 to 5 h after dosing. Increases in QT
at 30 and 90 mg/kg persisted for the duration of the test session. QT
after 3 mg/kg was increased relative to time-matched vehicle controls,
but was also increased during the predose period such that raw QT
increases at 3 mg/kg, relative to predose, wereminimal. QTca exhibited
dose and exposure-dependent increases following 10, 30, and 90 mg/kg
throughout the 22 h test session, with maximal increases generally
from 1.5 to 5 h after dosing (period mean increases 10, 20, and 54 ms,
respectively). Minimal, transient increases in QTca (b4 ms; b1 h) at
3 mg/kg relative to predose baseline were not signiﬁcant.4.4. Canine summary
A single oral dose of moxiﬂoxacin in the dog resulted in dose-
related increases in QTca at 10, 30, and 90 mg/kg. Transient increases
in QTca (b6 ms) occurred at 3 mg/kg but failed to achieve statistical
signiﬁcance. The dose–response and time course for the increases in
QTca are consistent with expectations regarding dose, maximum
exposures, time tomaximumexposures, and the rate of drug elimination
In addition, the projectedmoxiﬂoxacin exposure (Cmax, 3.1 μg/mL, total
drug) at the threshold dose in these studies (10 mg/kg) is similar to the
range of clinical moxiﬂoxacin exposures associated with QT-interval
prolongation (2.6–5.3 μg/mL) (Ollerstam et al., 2007), and is consistent
with the normalized responsiveness to moxiﬂoxacin presented in
Section 10.3. The change in QTca, normalized to moxiﬂoxacin exposure
(0.0004 ± 0.0002 Δms%/μM), was similar to that observed in all other
species (Fig. 51), differing signiﬁcantly only from the minipig.
QT rate-dependence exists in the dog, but was the least pro-
nounced compared to the other species examined. The dynamic QT–
RR range under normal conditions indicates a relatively small range
for QT (174 to 283 ms) relative to RR (440–1193 ms), and a ratio of
the QT/RR ranges and a slope of raw QT–RR that were less than that
for the other species, including humans. However, the data presented
herein indicate that correcting QT for noteworthy changes in heart rate
is still warranted. The RR-impact analysis described in Section 3.5 dem-
onstrated that a 20% change in RR interval is associated with a substan-
tial change in the rawQT. TheQT/QT–RR Slope Summary andRR-impact
analyses indicate that QTca and QTcV effectively resolved heart rate
dependence, QTcF was adequate, albeit not optimal, and QTcBwas un-
satisfactory. In addition, the analysis of mean square slopes indicated
that QTca, QTcV, and QTcF had low random and systematic variability,
and conﬁrmed the increased and controllable error in introduced by
QTcB. Finally, the QT/QT–RR slope summary for individual animals
demonstrated that QTca minimized inter-animal variability to the
greatest extent relative to the other correction methods. This was
consistent for all species examined. Given the low rate-dependence
of the raw QT, ﬁxed rate-corrections employing coefﬁcients that are
in near approximation to the optimal canine β value (QTcV and
QTcF) afford reliable estimates of QT prolongation (Fig. 10), albeit
with less precision than that afforded by an individual probabilistic
(QTca) correction. Although QTca is a recent development, from
both a regulatory and scientiﬁc perspective, the current evidence sup-
ports the use of individual probabilistic rate-corrections as the most
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current species.
The number of sites that provided data for the dog was adequate
for an analysis of site concordance. There was only a weak indication
for a site effect in the response to moxiﬂoxacin, despite site speciﬁc
differences in individual-animal correction coefﬁcients (β). When
included in the analysis as a covariate, RR interval was negative for
a site effect indicating that the site differences in β did not result
from the parabolic rate correction method used for QTca (log QT =
c + log RR + error). Site speciﬁc differences in β were not impacted
by body weight or age, though there may be other potential environ-
mental factors. Regardless, the ability to detect moxiﬂoxacin-induced
QT prolongation at each site, despite site differences in β, conﬁrms
the robustness of the current methods.
4.5. Canine ﬁgures
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Fig. 5. Canine QT–RR relationship. RR and QT populations were normally distributed
and under control conditions (2.5%b>97.5% quantiles) ranged from 440 to 1193 ms
for RR and from 174 to 283 ms for the raw QT. Data are equally weighted (~4K random
samples) derived from the entire canine population (n = 34) and clearly exhibit
rate-independent QT variability where multiple QT values are present for each discrete
Fig. 7. Canine raw QT summary. The raw QT interval increased in a dose-proportional
manner where the maximal changes were well-correlated with the PK proﬁle.
Expected raw QT shortening was observed during periods of RR shortening associated
with protocol-driven procedures (dosing, TK sampling, etc.). Data are composite values
from all sites which employed morning dosing (4 sites, n = 26).RR interval (see text).200
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Fig. 6. Canine RR summary. RR tended to shorten around Cmax (2–4 h) with increasing
doses (≥30 mg/kg) of moxiﬂoxacin. Following the 90 mg/kg dose, the RR interval
was signiﬁcantly decreased (150–200 ms) compared to vehicle treatment. Data are
composite values from all sites which employed morning dosing (4 sites, n = 26).
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Fig. 8. Canine QTca summary. The individually rate-corrected QTca interval exhibited
dose-proportional increases in both magnitude and duration. The peak increase
(~50 ms) was coincident with the established moxiﬂoxacin Tmax. The rate-associated
raw QT variability noted with vehicle treatment (Fig. 7) resolved with application of an
individual rate-correction (4 sites, n = 26).
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Fig. 9. Canine QT/QTc–RR slope summary. Individual QT/QTc–RR slopes are presented for
the raw QT interval without rate-correction (β = NA) and for the individual probabilistic
(QTca), Van de Water (QTcV), Fridericia (QTcF), and Bazett (QTcB) corrections (5 sites,
n = 34). While QTca yielded a nearly optimal slope of 0.0040 ± 0.010, both QTcV and
QTcF also reduced rate-dependence. For the dog, QTcB resulted in a consistent
rate-correction error and introduces an otherwise controllable error in this species (see
Figs. 10 and 11). Data are scaled for within-species inspection (panel A) and also at a
common scale (panel B) to facilitate cross-species comparisons. Data are arranged by
ascending β value where applicable.
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Fig. 10. Canine MSS summary. The efﬁcacy of each rate-correction method was assessed
as the MSS. Consistent with QTc–RR slopes (Fig. 9) the individual QTca correction was the
most efﬁcacious method. While QTcV and QTcF performed acceptably well, QTcB was
unsuited for use in this species where MSS was unchanged for the raw uncorrected QT
(5 sites, n = 34). Note that the canine MSS scale is ~10% of the range obtained with
cynomolgus monkey (Fig. 17).
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Fig. 11. Impact of heart rate changes on canine QT/QTc. To examine the comparative
effects of changes in heart rate on QTc, the RR reference cycle lengths were varied by
±20% for each QTc method, and the changes in ΔQTref expressed as the associated %
change. The raw QT exhibited the expected rate-dependent changes which were
effectively dissociated by the application of QTca, QTcV, and QTcF corrections. In contrast,
QTcB over-corrected the raw QT as RR shortened, and under-corrected as RR
was prolonged, demonstrating that this method is unsuited for use in the dog (5 sites,
n = 34).
Table 2
Canine QTref summary. Values for slope and θ are mean values for all vehicle treat-
ments (n = 34). An RRRef of 750 ms was used for the raw QT and QTca calculations
while QTcV, QTcF, and QTcB calculations employed an RRref of 1000 ms (see
text). The change in RRref resulted in an expected offset in QTref, but the derived
values remained in the physiological range. Results are graphically summarized in
Fig. 11.
Dog Slope θ ΔQTref
(RRRef − 20%)
QTRef ΔQTref
(RRRef 20%)
% ms ms ms %
QTraw 0.0901 155.1 −6.1 209 223 236 5.7
QTca 0.0040 221.3 −0.3 224 224 225 0.3
QTcV −0.0094 250.0 0.8 243 241 239 −0.8
QTcF −0.0159 259.2 1.3 246 243 240 −1.3
QTcB −0.0795 322.2 6.6 259 243 227 −7.0
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5.1. Introduction
Following issuance of the ICH S7B guidance (Anon) for CV
safety testing, the utilization of large animals for the preclinical
assessment of repolarization safety has steadily increased. Whereas
the foundation of modern non-rodent cardiovascular safety assess-
ment was largely based on canine experience (Hanson et al.,
2006), the cynomolgus monkey has emerged as an increasingly
important species. In recent years, this increase has been largely
attributable to the accelerating development of biologic agents
with 17 FDA approvals in 2012, and 5 during ﬁrst quarter of
2013 (Anonymous, 2013). In many cases, non-human primates may
be the only relevant species for pharmacology or toxicology studies
with certain biologics due to lack of activity in other species (Krejsa
et al., 2013). In addition to cross-reactivity with many human biolog-
ical agents, the cynomolgus monkey also expresses the relevant
72 H. Holzgrefe et al. / Journal of Pharmacological and Toxicological Methods 69 (2014) 61–101cardiac ion channels (Puppala et al., 2013; Watson et al., 2011) to en-
able the reliable translation of CV safety assessments to man.
While the value and utilization of the cynomolgus monkey
in CV safety assessment is well-established, speciﬁc guidance
regarding the assessment of possible drug effects on cardiac repo-
larization (QT interval) remains conspicuously absent. The Safety
Pharmacology Society recently provided their Best Practices for
CV safety assessments (Leishman et al., 2012). While aforemen-
tioned document acknowledged the issue of profound QT
rate-dependence in the primate, it failed to describe how this mat-
ter could, or should, be addressed. Indeed, the Best Practices
discussion acknowledged that although the primate was a widely
used and important model, proscriptive recommendations for ap-
propriate use were constrained by the current paucity of published
data.
As noted elsewhere in this report, there is now general recogni-
tion within the drug-development community that individual QT
rate-corrections are the most appropriate whenever a heart rate
correction is employed (Leishman et al., 2012). Hoverer, study
designs often generate limited CV data where the accurate deriva-
tion of an individual QT rate-correction is not possible. The latter
issue is of critical importance to both the drug-development
community and afﬁliated regulatory bodies. In the absence of an
individual rate-correction and lacking speciﬁc guidance, sponsors
(recognizing the intrinsic rate-dependence of the QT interval) may
resort to the application of a number of generic rate-correction
methods in the non-human primate (Ando et al., 2005; Chiang
et al., 2007; Fossa et al., 2005; Ishizaka et al., 2009; Sasaki, Shimizu,
Suganami, & Yamamoto, 2005; Taylor & Gleason, 2010). As such,
the consortium gathered high resolution telemetered data from
large and diverse cynomolgus monkey populations and character-
ized the associated QT and RR relationships and the responses to
moxiﬂoxacin.
In the current study, raw QT and RR data were provided for 37
cynomolgus monkeys at 5 sites following vehicle and treatment
with moxiﬂoxacin at 3, 10, 30, and/or 100 mg/kg. All ECG data were
analyzed at the respective sites as subsequently described and
provided to the consortium at a default resolution of 5 min. The
primary response to moxiﬂoxacin is described for QT corrected for
heart rate using an individual probabilistic rate-correction (QTca)
(Holzgrefe, Cavero, Gleason, Warner, et al., 2007). The efﬁcacies of
the most commonly used generic rate-corrections (QTcV, QTcF,
QTcB) are presented following vehicle (control) administration for
comparison.
5.2. Materials and methods
Summary data for 37 cynomolgus monkeys (4.34 ± 1.13 kg,
69.8 ± 35.9 months, 17 male, 20 female) at 5 sites (A, B, C, F, and G)
are presented. See Appendix Section 2.1.2 for site-speciﬁc housing,
data acquisition, and treatment details.
5.3. Results
5.3.1. QT–RR analysis
5.3.1.1. QT–RR distributions. Representative QT and RR pairs after
vehicle treatment for 37 cynomolgus monkeys are presented in
Fig. 12. The range for RR in the cynomolgus monkey is less than
in the dog, while the corresponding raw QT values for overlapping
RR intervals are much greater in the cynomolgus monkey. The
pronounced steepness of the QT–RR slope has a dramatic impact
on the QT rate-correction accuracy (see Section 10.1). RR and
QT populations were normally distributed and under control con-
ditions (2.5%b>97.5% quantiles) ranged from 240 to 776 ms for
RR (77 to 250 bpm) and from 140 to 359 ms for raw QT.5.3.1.2. Site concordance. The potential for systematic differences
between test sites was evaluated for the individual-animal correction
coefﬁcients (β) and the response to moxiﬂoxacin presented as ΔQTca
(%)/μM moxiﬂoxacin plasma concentration (Cmax). The site-speciﬁc
mean β values varied signiﬁcantly by source (0.5978 vs. 0.7531,
Mauritius vs. Chinese, p = 0.0028) (Ebeling et al., 2011) but this
difference did not affect the individual response to moxiﬂoxacin
where no site-speciﬁc effects were detected (see Appendix Section 2.2
for details).
5.3.1.3. QT/QTc–RR slope analysis. Individual QT/QTc–RR slopes
(Fig. 16A and B) demonstrate that QTca performed optimally
(−0.0043 ± 0.029). All generic rate-corrections were generally
equivalent and failed to dissociate the effects of rate from the raw
QT interval. With the exception of the guinea pig, the QT–RR slope
is markedly steeper in the cynomolgus monkey (see Section 10.1).
As with all species, pronounced inter-animal variability is clearly
evident.
5.3.1.4. MSS summary. Consistent with QTc–RR slopes (Fig. 17), QTca
demonstrated the only effective dissociation of the effects of
heart rate on the raw QT (MSS = 0.0008 ± 0.0019). All generic
corrections increased the QTc measurement error relative to the
individual QTca formulae. Assessed as the MSS, the relative efﬁcacy
of the generic rate-corrections improved as the associated β values
increased, but even QTcB retains marked rate-dependence (see
Fig. 18). All generic corrections are clearly unacceptable in this
species.
5.3.1.5. Impact of heart rate changes on QT/QTc. Table 3 highlights the
impact of a physiologically inappropriate RRref in any QT rate-
correction or normalization calculation. At a cycle length of 500 ms,
the raw QT in the cynomolgus monkey is ~240 ms and this can be
conﬁrmed from direct ECG measurements. When RRref is changed
to 1000 ms (as deﬁned within all generic correction formulae), the
associated QTc increases to ~400 ms. The latter QTc values exist at
the physiological extreme for this species and cannot be conﬁrmed
in vivo. The application of any generic QTc calculation which employs
a delta calculation (change from baseline, vehicle, or both) dramati-
cally ampliﬁes the associated QTc values, rendering accurate repolar-
ization assessment or direct comparison to other studies virtually
impossible. As summarized in Fig. 18, all generic rate-corrections
under-corrected the raw QT interval as cycle length shortened, and
over-corrected as cycle length prolonged relative to the reference
heart rate.
5.3.2. Moxiﬂoxacin
5.3.2.1. Exposure and pharmacokinetics. Limited moxiﬂoxacin plasma
were obtained at single site (A) and conformed to expected values. In
the absence of systematic plasma pharmacokinetics, published values
were used for the current PK–PD modeling where single doses of 3,
10, 30, 90, and 100 mg/kg were projected to yield moxiﬂoxacin
exposures (Tmax) of 0.69, 1.10, 3.40, 8.54, and 9.53 μg/mL (Watson
et al., 2011).
5.3.2.2. QT and RR effects. Time-course proﬁles for RR, raw QT, and
QTca after vehicle and moxiﬂoxacin administration are presented in
Figs. 13–15 for 4 sites which employed morning dosing (A, B, F,
and G). A single site employed afternoon dosing (C) and is not includ-
ed in the graphic summary due to pronounced diurnal QT and RR dif-
ferences relative to the time of dosing. Expected decreases in QT and
RR occurred during animal handing for dosing and toxicokinetic sam-
pling. Moxiﬂoxacin up to 100 mg/kg elicited no noteworthy effect on
heart rate. The raw QT (Fig. 14) exhibited increases in magnitude and
duration at all doses which were conﬁrmed with QTca where the
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Threshold signiﬁcant QTca prolongation was obtained at 10 mg/kg.
There is an apparent moxiﬂoxacin QTca effect at 3 mg/kg, but the
magnitude of the increase did not achieve statistical signiﬁcance. Im-
portantly, the application of QTca fully resolved the pronounced
rate-dependent raw QT changes observed in the vehicle group
(Fig. 14). The slight QTca increase during the dark phase of the photo-
period is expected, and likely associated with withdrawal of sympa-
thetic tone and a decrease in core body temperature (Mattu, Brady,
& Perron, 2002; van der Linde, Van Deuren, Teisman, Towart, &
Gallacher, 2008).100
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Fig. 12. Cynomolgus monkey QT–RR relationship. RR and QT populations (n = 37)
were normally distributed and under control conditions (2.5%b>97.5% quantiles)
ranged from 240 to 776 ms for RR (77 to 250 bpm) and from 140 to 359 ms for raw
QT. Similar data for the dog are presented for comparison (RR range 440 to 1193 ms;
raw QT 174 to 283 ms) Data are equally weighted (~4K random samples) from both
populations. Similar pronounced rate-independent QT variability is evident in both
species.
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Fig. 13. Cynomolgus monkey RR summary. RR shortened with dose administration
(t = 0), and demonstrated the expected diurnal changes. No signiﬁcant dose-related
changes were noted. Data are composite values from all sites which employed morning
dosing (4 sites, n = 31).5.4. Cynomolgus monkey summary
Single oral doses of moxiﬂoxacin in the cynomolgus monkey
resulted in dose-proportional increases in QTca at 10, 30, 90, and
100 mg/kg. Transient increases in QTca (6–10 ms) occurred at
3 mg/kg but failed to achieve persistent statistical signiﬁcance.
The dose response and time course for the increases in QTca were
consistent with expectations regarding dose, maximum exposures,
time to maximum exposures, and the rates of drug elimination
(Henriques et al., 2010; Holzgrefe, Cavero, Buchanan, et al., 2007;
Watson et al., 2011). The mean QTca AUC centered on 1 h at Tmax and
normalized to moxiﬂoxacin exposure (0.0007 ± 0.0004 Δms%/μM) was
similar to that observed in all other species (Fig. 51), differing signif-
icantly only from the minipig. For demonstration of assay sensitivity,
a single 30 mg oral dose of moxiﬂoxacin provides a reproducible
QTca response in the range of threshold repolarization concern
(10–20 ms/18 h duration) and could serve as a reliable positive
control.
The QT–RR relationship of the cynomolgus monkey differs
dramatically from all other preclinical species. In particular, the very
steep and unique QT rate-dependence (Fig. 49) renders the generic
QT rate-corrections (QTcV, QTcF, and QTcB) mathematically inappro-
priate and utterly ineffective in this species. As previously noted,
the use of individual rate-corrections has been recognized as the
preferred method in the cynomolgus monkey, but in the absence
of sufﬁcient data, a ﬁxed rate-correction factor has to be employed.
In the current study, individual rate-correction coefﬁcients were
obtained from 37 animals at 5 sites which included subjects of both
Mauritius and Chinese origin. The current mean individual β value
(0.686) is far greater than for QTcB (0.5) and was the only
rate-correction coefﬁcient which effectively dissociated the effects of
rate, necessary for an accurate repolarization risk assessment. Given
the demographic diversity of the current study population, and the
uniform rate-correction efﬁcacy demonstrated across the current sub-
jects, the current mean β value merits consideration as a cynomolgus
monkey-speciﬁc ﬁxed correction factor where an individual rate-
correction is not feasible.
The number of sites that provided data for the cynomolgus mon-
key enabled a robust analysis of site concordance. While there was
only a weak indication for a site effect in the response to moxiﬂoxacin
(assessed as the normalized QTca AUC), the demographic analysis
demonstrated a signiﬁcant source effect (Mauritius vs. Chinese) in
the individual animal rate-correction coefﬁcients (β values). The
current distinct, source-speciﬁc QT–RR proﬁles are consistent with
other reports which have described genotypic variances in the
cynomolgus monkey that were clearly source-related (Ebeling et al.,
2011). Source-speciﬁc differences in β values were not impacted by
body weight or age. The ability to detect a uniform moxiﬂoxacin-
induced QTca effect at each site, despite source differences in baseline
QT–RR relationships (β value), conﬁrms the robustness and site
portability of the current methods. See Appendix Section 1.3 for
details.5.5. Cynomolgus monkey ﬁgures
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Fig. 14. Cynomolgusmonkey rawQT summary. The rawQT interval paralleled changes in
the RR interval with dose-dependent prolongation evident at all doses. The magnitude
and duration of moxiﬂoxacin-associated QT increase was well-correlated with reported
moxiﬂoxacin pharmacokinetics. Data are composite values from all sites which employed
morning dosing (4 sites, n = 31).
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Fig. 15. Cynomolgus monkey QTca summary. The individually rate-corrected QTca
interval exhibited dose-proportional increases in both magnitude and duration.
The peak increase (~35 ms) was coincident with the expected moxiﬂoxacin Tmax.
Importantly, the rate-associated raw QT variability noted with vehicle treatment
(Fig. 14) resolved with application of QTca. Data are composite values from all sites
which employed morning dosing (4 sites, n = 31).
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Fig. 16. Cynomolgus monkey QT/QTc–RR slope summary. The cynomolgus monkey
QT–RR relationship (n = 37) is characterized by a steep slope compared to both the
dog and human (mean 0.0.334 ± 0.090) such that none of the generic rate-
corrections dissociated the effects of rate. In contrast, QTca fully dissociated the effects
of rate (−0.0042 ± 0.0029). Inter-individual variability is clearly evident, and was
unaffected by any of the generic rate-corrections. Data are scaled for within-species
inspection (panel A) and also at a common scale (panel B) to facilitate cross-species
comparisons. Data are arranged by ascending β value where applicable.
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Fig. 17. Cynomolgus monkey MSS summary. The efﬁcacy of each rate-correction
method was assessed as the MSS (n = 37). Consistent with QTc–RR slopes (Fig. 16),
the individual QTca correction was the most efﬁcacious method. While the other
methods progressively reduced MSS as the β value increased (see text), all generic
rate-corrections were associated with signiﬁcant, controllable measurement errors,
and were deemed unsuitable for use in this species.
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Fig. 18. Impact of heart rate changes on cynomolgus monkey QT/QTc. To examine the
comparative effects of changes in heart rate on QTc, the RRref was varied by ±20%, and
the changes in ΔQTref expressed as the associated % change for each QTc method.
The raw QT exhibited the expected rate-dependent changes which were effectively
dissociated only by the application of an individual QTca. Consistent with the associated
MSS, all generic rate-corrections demonstrated marked rate-dependence and are
unacceptable for use in this species.
Table 3
Cynomolgus monkey QTref summary. Values for slope and θ are mean values for all
vehicle treatments (n = 37). An RRref of 500 ms was used for the raw QT and QTca
calculations while QTcV, QTcF, and QTcB calculations employed an RRref of 1000 ms.
Importantly, an RRref of 1000 ms results in an offset of 150–160 ms in the associated
QTc values, confounding the accurate assessment of possible drug-associated QTc
effects (see text). Results are graphically summarized in Fig. 18.
Cynomolgus Slope θ ΔQTRef
(RRref − 20%)
QTRef ΔQTRef
(RRref 20%)
% ms ms ms %
QTraw 0.3185 81.5 −13.2 209 241 273 11.7
QTca −0.0046 245.1 0.2 243 243 242 −0.2
QTcV 0.2346 166.4 −11.7 354 401 448 10.5
QTcF 0.2000 203.1 −9.9 363 403 443 9.0
QTcB 0.1043 290.2 −5.3 374 394 415 5.0
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6.1. Introduction
The use of swine in basic cardiovascular research has a long history
reﬂecting the wide variety of disease/efﬁcacy models that are viable
due to the high degree of anatomical, physiological, and patho-
physiological correspondence to man (Swindle, 1992, 2007; Swindle,
Makin, Herron, Clubb, & Frazier, 2012; Tumbleson, 1996). To over-
come a practical impediment to the utilization of swine as a research
model, selective breeding programs have been instituted to produce
“miniature” swine with essentially unaltered anatomical and physio-
logical characteristics, but with lower growth trajectories and, ulti-
mately, signiﬁcantly decreased overall peak body weight/size
proﬁles compared to agricultural breeds. These initiatives have
resulted in several common minipig breeds including Yucatan,
Hanford, Sinclair, Gottingen, and others. To date, the best character-
ized among several alternative breeds is the Gottingen minipig, origi-
nally produced between 1961–1964 by a combination of Minnesota
(Hormel Institute), Vietnamese, and German Landrace stock (Forster,
Ancian, Fredholm, Simianer, & Whitelaw, 2010; Forster, Bode,Ellegaard, & van der Laan, 2010; Svendsen, 2006). In the intervening
decades, this breed has been increasingly utilized in toxicology
(Bode et al., 2010; Gad, Dincer, Svendsen, & Skaanild, 2007; Ikeda,
Friedman, & Hattan, 1998; Svendsen, 2006), and more recently in
cardiorespiratory and central nervous system safety pharmacology
studies (Bode et al., 2010; Redfern & Valentin, 2011).
Despite their widespread incorporation in pathophysiological and
efﬁcacy modeling, and accepted utilization in dermal and general
toxicology testing, miniature swine are not yet considered equivalent
to classic regulatory safety assessment models such as the canine and
nonhuman primate (Baird, Dalton, & Gauvin, 2013; Leishman et al.,
2012). Although pigs readily learn associative behaviors and operant
tasks (Bode et al., 2010), swine are very seldomused in neurobehavioral
or neurotoxicological safety studies (van der Laan, Brightwell,
McAnulty, Ratky, & Stark, 2010). Moreover, while the cardiopulmonary
systems of swine are generally comparable to the human (Bode et al.,
2010; Swindle, 2007), a multinational pharmaceutical industry survey
in 2001 indicated that most laboratories routinely utilized the beagle
dog and cynomolgusmonkey for electrocardiographic safety evaluation,
rather than swine (Hammond et al., 2001). Recent efforts have better
deﬁned the minipig as a general model in safety pharmacology and, in
particular, as a predictive system for cardiovascular (CV) safety assess-
ment (Authier et al., 2011; Hashimoto, 2008; Kano et al., 2005;
Laursen, Olesen, Grunnet, Mow, & Jespersen, 2011; Markert et al.,
2009; Redfern & Valentin, 2011; Stubhan et al., 2008; van der Laan
et al., 2010).
Although swine, including minipigs, have been used as models for
the study of electrophysiology and cardiac arrhythmias (Authier et al.,
2011; Hamlin, Burton, Leverett, & Burns, 1975; Hashimoto, 2008;
Kano et al., 2005; Laursen et al., 2011; Markert et al., 2009; Stubhan
et al., 2008; Sugiyama et al., 2011; van der Laan et al., 2010), there
are somedifferences in cardiovascular anatomy and electrocardiography
between swine and other species, including man. Like all quadrupeds,
the position and orientation of the heart is different than in the
human, requiring adjustments to standard lead conventions when
using surface electrodes (Nahas, Baneux, & Detweiler, 2002). As
with other preclinical species, adequate representation of the ECG is
less of an issue when employing epicardial leads (Cavero, 2010;
Hamlin et al., 1975; Henriques et al., 2010; Holzgrefe, Cavero,
Buchanan, et al., 2007; Holzgrefe, Cavero, Gleason, et al., 2007). Anatom-
ical differences also exist in the conduction system of the porcine
heart, which has augmented neuromyogenic components, including
adrenergic and cholinergic nerve ﬁbers in the AV node and bundle
branches, larger andmore differentiated Purkinje ﬁbers and endocardi-
al–epicardial Purkinje ﬁber distribution (Hamlin, 2005; Swindle, 2007).
While the impact of these distinctions in regulatory CV drug safety
assessment is currently unclear, there is accumulating evidence
that the electrophysiological basis for acquired (drug-induced) repolar-
ization delay is conserved across species including the canine,
nonhuman primate, and minipig (Laursen et al., 2011; Lu, Remeysen,
Somers, Saels, & De Clerck, 2001; Lu, Vlaminckx, Cools, & Gallacher,
2012).
While swine are a relatively novel regulatory CV test system, the
species has been used extensively in CV evaluations including
myocardial infarction, cardiopulmonary bypass and transplant, car-
diovascular catheterization, valvular surgery, epicardial pacemaker
and device implantation, and determinations of chronic drug
cardiotoxicity (Gad et al., 2007; Ikeda et al., 1998; Svendsen, 2006;
Swindle, 2007). The minipig has been found to be suitable for the
evaluation of blood pressure, heart rate and rhythm, and conduction
abnormalities, demonstrating cardiovascular function that is often
more similar to human than alternative models (Gad et al., 2007;
Swindle, 2007). The principal minipig cardiac ion channels are similar
to man, including those mediating primary sodium, calcium, and po-
tassium (IKr, IKs) currents (Laursen et al., 2011). Normative minipig
CV parameters and the effects of various standard pharmacological
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Fig. 19. Minipig moxiﬂoxacin PK (Site F). In contrast to the other species in this
report, the minipig demonstrated markedly prolonged moxiﬂoxacin clearance
where >90% of the initial dose was present at 24 h following the 100 mg/kg dose.
The prolonged moxiﬂoxacin clearance was mirrored in the associated QTca
(Fig. 23), demonstrating the efﬁcacy of QTca as an effective biomarker for
moxiﬂoxacin plasma exposure.
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and nonhuman primate (Ainsworth, Rotchford, Dua, & King, 2006;
Authier et al., 2011; Baird et al., 2013; Gauvin, Tilley, Smith, & Baird,
2009; Hashimoto, 2008; Kano et al., 2005; Markert et al., 2009;
Stubhan et al., 2008). These ﬁndings suggest that the minipig repre-
sents an additional, suitable model for regulatory CV assessments
(Bode et al., 2010).
6.2. Materials and methods
Summary data from 3 male and 9 female minipigs (16.83 ±
3.80 kg, 10.92 ± 3.06 months) at 2 sites (E and F) are presented.
See Appendix Section 2.1.4 for site-speciﬁc housing, data acquisition,
and treatment details.
6.3. Results
6.3.1. QT–RR analysis
6.3.1.1. QT–RR distributions. Representative QT and RR pairs after
vehicle treatment for 12 minipigs are presented in Fig. 20. While
the range of RR in the minipig is similar to the dog, the corresponding
QT intervals for a speciﬁc RR interval exhibit a wider range in the
minipig. RR and QT populations were normally distributed and
under control conditions (2.5%b>97.5% quantiles) ranged from 358
to 1055 ms for RR (63 to 168 bpm) and from 206 to 430 ms for raw
QT.
6.3.1.2. Site concordance. There was clear dose-dependence in the re-
sponse to moxiﬂoxacin but no indication for a difference between
the two sites. Note that as the intercept was not signiﬁcant, the use
of a linear model was supported (see Appendix Section 2.2 for de-
tails). Themodel using dose as factor also did not yield any indication
for a site difference.
6.3.1.3. QT/QTc–RR slope analysis. Individual QT/QTc–RR slopes (Fig. 24A
and B) demonstrate that QTca performed optimally (−0.0040 ±
0.010). While all generic rate-corrections partially dissociated the
effects of rate from the raw QT interval, pronounced inter-animal var-
iability is clearly evident. The application of QTcB resulted in a mean
QTc–RR slope of −0.0276 ± 0.052, consistent with near approxima-
tion of the associated β value (0.5) with the mean individual β value
(0.428 ± 0.115).
6.3.1.4. Minipig MSS summary. Consistent with QTc–RR slopes, QTca
demonstrated the most effective dissociation of the effects of heart
rate (Fig. 25) on the raw QT (MSS = 0.001 ± 0.001). All generic
corrections increased the QTc measurement error relative to the indi-
vidual QTca formulae. Assessed as the MSS, QTcB (β value = 0.5)
increased measurement error relative to QTca (β value = 0.428),
but was superior to the other generic methods and would yield
acceptable accuracy in this species if individual rate-corrections were
not feasible.
6.3.1.5. Effect of heart rate changes on QT/QTc. To examine the practical
impact of rate-correction performance, QTc was derived for each
correction method at RR intervals associated with 20% increases and
decreases from RRref (Fig. 26, Table 4). The raw QT exhibited the
expected rate-dependent changes which were completely dissociated
by the application of QTca. In the absence of an individual rate-
correction, QTcB yielded an error of ±1.5% and provided meaningful
decreases in the associated QTc measurement error. This outcome
is in accordance with the generic β value (QTcB = 0.5) which
approximates the mean individual β value (0.428 ± 0.115). QTcV
and QTcF under-corrected the raw QT as RR shortened and over-
corrected as RR was prolonged. In the absence of an individualrate-correction, QTcB corrects QT for heart rate changes with accept-
able accuracy (e.g. in toxicity studies employing strip chart ECGs
with a limited number of cardiac cycles). As noted in Table 4,
the generic RRref of 1000 ms prolonged QTref by ~50 ms compared
to the species-speciﬁc RR ref of 750 ms. While this offset would
likely not affect assay sensitivity where QTc was assessed as an
absolute change, it would impact delta QTc calculations (change
from baseline, time-matched vehicle, or both), resulting in an
artifactual increase in the associated result. Such an offset should
be considered when directly comparing results across methods and
sites.6.3.2. Moxiﬂoxacin
6.3.2.1. Exposure and pharmacokinetics. Moxiﬂoxacin plasma concen-
trations were separately determined at sites E and F. At site F,
full PK sampling was performed at each exposure level, with
collections designated as predose (0 h), and 0.25, 0.5, 1, 2, 4, 8,
and 24 h post-dose. At site E, exposures were conﬁrmed by
limited sampling performed at predose (0 h), and 4 and 24 h post-
dose.
Exposures at site F (Fig. 19) were 0.493, 1.597, and 3.562 μg/mL
and 0.154, 0.545, and 2.952 μg/mL at 4 h and 24 h post-dose
following 10, 30, and 100 mg/kg, respectively. At site E, similar
exposures were noted at 4 h (0.293, 0.857 and 3.871 μg/mL)
and 24 h post-dose (0.15, 0.43, and 2.1 μg/mL) for 10, 30, and
100 mg/kg, respectively. Moxiﬂoxacin plasma concentrations were
generally consistent with expected levels (Markert et al., 2009;
Siefert et al., 1999) and demonstrated markedly prolonged clearance
compared to other preclinical non-rodent species.
6.3.2.2. QT and RR effects. Time-course proﬁles for RR, uncorrected
QT, and QTca after vehicle and moxiﬂoxacin administration are
presented in Figs. 21–23. Expected decreases in the QT and RR
interval occurred during dosing and toxicokinetic sampling in all
dose groups with a return to baseline approximately 2 h after dosing
and up to 5 h after bleeding and feeding. Feeding was done at 4 h
post-dose (immediately after TK bleeding) and may have inﬂuenced
the recovery to baseline. With 100 mg/kg moxiﬂoxacin, the RR interval
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through ~18 h post-dose. No other noteworthy effects on heart rate
were observed. Raw QT was increased moderately at 10 and 30 mg/kg
and markedly at 100 mg/kg. Peak effects occurred from 1.5 to 5 h
post-dose and persisted until the end of the recording period with the
100 mg/kg dose. Persistent increases in QTca occurred in a dose- and
exposure-dependent manner at 10, 30, and 100 mg/kg, with the most
prominent effects between 2 and 8 h of approximately 9, 20, and
41 ms, respectively. QTca recovered to baseline levels at approximately
15 h post-dosewith 10 and 30 mg/kg. The pronounced increase in QTca
at 100 mg/kg persisted until the end of the recording period (≥24 h),
consistent with the markedly prolonged plasma clearance at this dose
(Fig. 19).150
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Fig. 20.Minipig QT–RR relationship. RR and QT populations were normally distributed,
and under control conditions (2.5%b>97.5% quantiles) ranged from 358 to 1055 ms for
RR (63 to 168 bpm), and from 206 to 430 ms for the raw QT. Similar data for the dog
are presented for comparison (RR range 440 to 1193 ms; raw QT 174 to 283 ms)
Data are equally weighted (~4K random samples from both populations). Rate-
independent variability is clearly evident (see text).
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Fig. 21. Minipig RR summary. The RR interval exhibited the expected environmental
(dosing and feeding) and diurnal effects. With 100 mg/kg moxiﬂoxacin, the RR interval
shortened by ~100 ms from 3 to 6 h post-dose, and remained decreased through ~18 h
post-dose. Data are from two sites (n = 12).6.4. Minipig summary
QT prolonging reference drugs such as haloperidol, sotalol,
terfenadine ormoxiﬂoxacin have been administered tominipigs by sev-
eral investigators andwere found to have tested positive in this species,
albeit using different correction methodologies (Authier et al., 2011;
Laursen, Grunnet, Olesen, Jespersen, & Mow, 2011; Markert et al.,
2009; Sugiyama et al., 2011). In the current study, QTca interval dura-
tions returned to baseline 15 h post-dose with 10 and 30 mg/kg, but
remained elevated for the duration of the recording interval at
100 mg/kg, similar to previous reports where 0, 100, and 300 mg/kg
elicited 6, 17, and 22% increases corresponding to approximately 20,
60, 77 ms (Markert et al., 2009). The mean QTca AUC centered on 1 h
at Tmax and normalized to moxiﬂoxacin exposure (0.0016 ±
0.0005 Δms%/μM) was signiﬁcantly greater than was observed in all
other species (Fig. 51).
The extended moxiﬂoxacin QTca effect is consistent with
prolonged clearance compared to the dog and monkey and could be
partly due to a longer and variable gastric emptying duration in the
minipig, compared to other species (Milano, 2012). A gastric empty-
ing half-time of 258 min was determined in minipigs by gamma scin-
tigraphy (Val-Laillet, Guerin, & Malbert, 2010). In contrast, gastric
emptying times of >24 h were noted in the Yucatan minipigs with
the Heidelberg pH capsule system (Oberle & Das, 1994). As such,
fasting minipigs overnight does not necessarily eliminate possible
food effects the next morning, with a potential delay in the absorp-
tion and elimination of test compounds after an overnight fast.
Moreover, minipigs should not be fed during critical times as the
RR interval is shortened by administration of food for ≥3 h
(Stubhan et al., 2008).
When comparing slopes of the different correction methods in the
minipig, the individual QTca was the most efﬁcacious method, where
the slope approached null. In the absence of an individual rate-
correction, QTcB yielded acceptable results as the associated β value
(0.5) approximated the mean individual β value (0.428). This is in
contrast to prior observations where QTcF was deemed the most
accurate generic correction (Authier et al., 2011; Kano et al., 2005).
A previously reported β value (n = 4; 0.2862) was within the current
range (0.2458–0.5886) but the cited derivation did not account for
rate-independent QT variability and was based on a small population
(Kano et al., 2005).
The magnitude of the QTca increase as a function of exposure was
higher in the minipig compared to all other species used in these
studies. Whether this QTca effect reﬂects differential repolarization
sensitivity or is primarily related to extend clearance is currently
unclear, although the latter seems more likely. In vitro data demon-
strating relatively less sensitivity of minipig cardiac tissues to repo-
larization changes and/or indices of proarrhythmia in ex vivo
preparations suggests that the current prolonged QTca effect is pri-
marily related to extend clearance (Lu et al., 2001, 2012), supporting
QTca as an accurate biomarker for moxiﬂoxacin PK.6.5. Minipig ﬁgures
240
280
320
360
400
-2 2 6 10 14 18 22
m
s
Hours
Veh
10 mg/kg
30 mg/kg
100 mg/kg
Fig. 23. Minipig QTca summary. QTca effectively dissociated the effects of heart rate
from the raw QT (Fig. 22), revealing a clear dose-dependent prolongation which
persisted for the duration of the observation period with the 100 mg/kg dose.
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Fig. 24. Minipig QT/QTc–RR slope summary. QTca yielded a nearly optimal QTc–RR
slope of−0.0040 ± 0.010 (n = 12). While all generic rate-corrections partially disso-
ciated the effects of rate from the raw QT interval, pronounced inter-animal variability
is clearly evident. QTcB yield a mean slope similar to that obtained with QTca (see
text). Data are scaled for within-species inspection (Panel A) and also at a common
scale (Panel B) to facilitate cross-species comparisons. Data are arranged by ascending
β value where applicable.
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Fig. 22. Minipig raw QT summary. Moxiﬂoxacin elicited a dose-dependent increase in
the raw QT interval which persisted for 20 h (10 mg/kg) or for the duration of the
observation period (30 and 100 mg/kg). The predose baseline values differed (18–
20 ms) between the vehicle and active treatments, consistentwith the shorter RR intervals
(−50 to−70 ms) noted in the vehicle group (Fig. 21). The impact of RR was effectively
resolved by application of QTca (Fig. 23).
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Fig. 25.Minipig MSS summary. Consistent with the QTc–RR slopes, the individual QTca
correction was the most efﬁcacious method. QTcV and QTcF progressively reduced MSS
as the β value increased (Fig. 24). The QTcB β value (0.5) was greater than the mean
QTca value (0.428) and increased measurement error relative to QTca, but was superi-
or to the other generic methods and yielded acceptable accuracy in this species.
78 H. Holzgrefe et al. / Journal of Pharmacological and Toxicological Methods 69 (2014) 61–101
-15
-10
-5
0
5
10
15
+20% RR-20% RR
Δ 
QT
 R
ef
 (%
)
QT Raw
QTca
QTcV
QTcF
QTcB
Fig. 26. Impact of heart rate changes on minipig QT/QTc. The raw QT exhibited the
expected rate-dependent changes which were effectively dissociated by the applica-
tion of the individual QTca and QTcB, which employed similar β values (0.428 and
0.5, respectively). As evidenced by the associated MSS (Fig. 25) optimal rate-
dissociation was only achieved with QTca whereas QTcV and QTcF under-corrected
the raw QT as RR shortened and over-corrected as RR was prolonged. However, the
generic application of QTcB conveys adequate assay sensitivity in the absence of an
individual rate-correction in this species.
Table 4
Minipig QTref summary. Values for slope and θ are mean values for all vehicle treat-
ments (n = 12). An RRref of 750 ms was used for QT raw and QTca calculations
while QTcV, QTcF, and QTcB calculations employed an RRref of 1000 ms (see text).
Results are summarized in Fig. 26.
Minipig Slope θ ΔQTRef
(RRref − 20%)
QTRef ΔQTRef
(RRref 20%)
% ms ms ms %
QTraw 0.2005 168.566 −9.4 289 319 349 8.6
QTca 0.0040 316.302 −0.2 319 319 320 0.2
QTcV 0.1135 255.982 −6.1 347 369 392 5.8
QTcF 0.0624 304.703 −3.4 355 367 380 3.3
QTcB −0.0276 389.880 1.5 368 362 357 −1.5
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7.1. Introduction
The characteristics and propensities of the marmoset have engen-
dered their use in a wide range of human research models including
physiology, drug metabolism, general toxicology, and reproductive
biology (Isobe et al., 2012; Michel, Wood, Hofbauer, Corvol, & Menard,
1984; Zuhlke & Weinbauer, 2003). The principal utility of the common
marmoset in research derives from their genetic similarity to humans,
where they have been used as a pharmacological model for several
diseases including psychological disorders and multiple sclerosis
(Galvao-Coelho, Silva, Leao Ade, & de Sousa, 2008; Genain & Hauser,
1997). Furthermore, the homology of cytochrome P450 in the common
marmoset liver lies at a midpoint between human and non-primate
experimental animals, including the dog, rabbit, guinea pig, rat,
mouse, and hamster (Igarashi, Sakuma, Isogai, Nagata, & Kamataki,
1997). Thus, the marmoset has become well-established as an experi-
mental model for the prediction of human response in nonclinical
studies.
In the early stages of drug development compound supplies are
often very limited, but early stage QT risk assessments are often neces-
sary to guide rational drug design (Honda et al., 2011; Tabo, Kimura, &
Ito, 2007; Tabo et al., 2010). In contrast to the large animal models
which may require a large amount of test compound, the marmoset
(~300–400 g) offers an alternate test system which has demonstrateddiverse preclinical utility. Several compounds which affect the cardio-
vascular conduction system in man have demonstrated responses in
the telemetered marmoset which were well-correlated to clinical
outcomes, including QT interval prolongation (Horii et al., 2002; Tabo
et al., 2008).
The QT interval in common marmoset exhibits substantial rate-
independent variability, similar to that previously reported in the
cynomolgus monkey and dog (Holzgrefe, Cavero, Gleason, Warner,
et al., 2007). Employing probabilistic QT analysis, the raw QT interval
in the telemetered marmoset has been precisely corrected for the
effects of heart rate and demonstrated sensitivity to moxiﬂoxacin at
relevant therapeutic exposures (Honda, Komatsu, Isobe, Tabo, &
Ishikawa, 2013; Komatsu et al., 2010). These data indicate that appli-
cation of this method in the common marmoset results in a high
degree of sensitivity for the consistent detection of small (5–10 ms)
changes in the QTc interval as is characteristic in the clinical Thorough
QT/QTc (TQT) study.
In the current study, raw QT and RR data were provided by 2 sites
(B: n = 8 and C: n = 6) following vehicle and treatment with
moxiﬂoxacin at 10, 30, and 100 mg/kg (site B) or 90 mg/kg (site C).
All ECG data were analyzed at the respective sites and provided to
the consortium at a default resolution of 5 min.
7.2. Materials and methods
Aggregate data from 14 marmosets (0.52 ± 0.71 kg, 40.2 ±
14.4 months, 7 male, 7 female) at 2 sites (B and C) are presented. ECG
data from site B were derived from previously published studies
(Honda et al., 2010; Komatsu et al., 2010) in common marmosets and
were reanalyzed for the consortium to enable cross-species and cross-
site comparisons. Data from site C have not been previously disclosed.
See Appendix Section 2.1.3 for housing, data acquisition, and treatment
details.
7.3. Results
7.3.1. QT–RR analysis
7.3.1.1. QT–RR distributions. Mean QT and RR data after vehicle treat-
ment (n = 14) are presented in Fig. 27. RR and QT populations were
normally distributed and the dynamic ranges under control conditions
(2.5%b>97.5% quantiles) ranged from 198 to 521 ms for RR (115 to
303 bpm) and from 76 to 192 ms for QT.
7.3.1.2. Site concordance. The potential for systematic parameter
differences between test sites could not evaluated due to the limited
number of sites (n = 2) which employed different doses and admin-
istration times.
7.3.1.3. QT/QTc–RR slope analysis. Individual QT/QTc–RR slopes indicated
that QTca performed optimally (0.008 ± 0.038). As illustrated in
Fig. 31, all generic rate-corrections substantially reduced QTc measure-
ment error compared to the raw QT. It also is apparent from Fig. 31 that
QTca minimized heterogeneity in the QTca–RR slopes across all
animals, whereas heterogeneity for the generic corrections was similar
to or increased relative to raw QT–RR slope.
7.3.1.4. MSS summary. To further evaluate the performance of the QT
rate-corrections, individual linear QTc–RR regressions were performed
for all vehicle treatments and the means of the squared QTc–RR slopes
(MSS) were derived (Fig. 32). Consistent with QTc–RR slopes (Fig. 31),
the individual QTca correction was the most efﬁcacious method in the
marmoset, evidenced by lowest MSS (0.0014 ± 0.0019). All generic
rate-correction methods reduced MSS compared to the raw QT and
would be expected to provide meaningful but less sensitive results
than expected with an individual rate-correction.
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Fig. 27.Marmoset QT–RR relationship. RR and QT populations (n = 14) were normally
distributed, and under control conditions (2.5%b>97.5% quantiles), ranged from 198 to
521 ms for RR (115 to 303 bpm) and from 76 to 192 ms for the raw QT. Similar data for
the dog are presented for comparison (RR range 440 to 1193 ms; raw QT 174 to
283 ms). Data are equally weighted (~4K random samples from both populations).
Rate-independent variability is clearly evident (see text).
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Fig. 28. Marmoset RR summary. Compared to vehicle, there were no signiﬁcant
treatment-associated changes in the RR interval. Environmental effects (dosing, room
entry, and diurnals changes) are clearly evident and similar across all treatment
groups. Data are from a single site employing morning dosing (n = 8).
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cal impact of rate-correction performance, QTc was derived for each
correction method at RR intervals associated with 20% increases and
decreases from RRref (Fig. 33, Table 5). The raw QT exhibited the
expected rate-dependent changes which were fully dissociated by
the application of QTca. As illustrated in Fig. 33, QTcV and QTcF
exhibited substantial rate-dependence and over-corrected the raw
QT as the RR shortened and under-corrected as the RR prolonged. In
contrast, QTcB largely dissociated the effects of rate, consistent with
the near approximation of the ﬁxed Bazett β value (0.5) to the opti-
mal individual β value (0.446 ± 0.106).
7.3.2. Moxiﬂoxacin
7.3.2.1. Exposure and pharmacokinetics. The moxiﬂoxacin plasma
values used for the current PK–QTca modeling have been previously
reported (Komatsu et al., 2010). The maximum total plasma concen-
trations (Cmax) after administration of moxiﬂoxacin were 2.2 ± 0.2,
6.5 ± 0.5 and 16.5 ± 1.6 μg/mL at 10, 30, and 100 mg/kg, respectively.
The associated Tmax values were 1.1 ± 0.3, 1.1 ± 0.3, and 1.4 ± 0.3 h
at 10, 30, and 100 mg/kg, respectively.
7.3.2.2. QT and RR effects. Time-course proﬁles for RR, raw QT, and
QTca after vehicle and moxiﬂoxacin administration are presented in
Figs. 28–30. Expected decreases in QT and RR occurred during animal
handing for dosing and toxicokinetic sampling. Moxiﬂoxacin elected
dose- and exposure-dependent increases in QTca at 10, 30, and
100 mg/kg. Sustained increases at these doses were approximately
6, 10, and 30 ms for 10, 30, and 100 mg/kg, respectively, during the
2–4 h post-dose period.
7.4. Marmoset summary
As shown in Fig. 51, the normalized responsiveness to moxiﬂoxacin
at Tmax was equivalent to that in man demonstrating that the
telemetered common marmoset, in conjunction with the application
of the probabilistic QT analytical method, can detect QT interval prolon-
gation following moxiﬂoxacin administration with a level of sensitivity
similar to that obtained in a clinical TQT study.
In comparison to the generic Bazett, Fridericia, and Van de Water
formulae, individual probabilistic QT rate-correction minimized vari-
ability for the individual QTc–RR regressions where the slopes of the
individual probabilistic QTc–RR relationships approached zero in all
subjects. Raw QT intervals obtained from each diurnal photoperiod
showed expected rate-dependent variability which was resolved by
application of QTca. The estimated changes in ΔQTRef for QTca
approached null (±1%), whereas those for QTcF and QTcV were
> ± 5%.
These results demonstrate that the application of probabilistic QT
analysis represents a best practice for correcting QT intervals in
telemetry studies with common marmosets. The Bazett correction
was superior to other generic methods in this species and would be
preferred in the absence of an individual rate-correction.
The raw QT and RR intervals exhibited a clear circadian rhythm
(Honda et al., 2010, 2013). QTca intervals, which were dissociated
from the effects of heart rate, were increased by approximately
10 ms during the night period. Recent studies have demonstrated
that the sympathetic/parasympathetic nervous systems are involved
in diurnal QTca variation in common marmosets (Honda et al.,
2013). Body temperature is also known as one of the physiological
factors modulating QT intervals. Hypothermic QT interval prolonga-
tion has been demonstrated in dogs (van der Linde et al., 2008),
man and minipigs (Mattu et al., 2002). Taken together, the nocturnal
QTca increase is consistent with changes in the autonomic activity
and/or the decreases in core body temperature.7.5. Marmoset ﬁgures
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Fig. 31. Marmoset QT/QTc–RR slope summary. Individual QT/QTc–RR slopes are
presented for the raw QT interval without rate-correction and for the Van de Water
(QTcV), Fridericia (QTcF), Bazett (QTcB), individual (QTca) corrections (n = 14).
QTca yielded a nearly optimal QTc–RR slope of 0080 ± 0.038. While all generic rate-
corrections partially dissociated the effects of rate from the raw QT interval, pro-
nounced inter-animal variability is clearly evident. Data are scaled for within-species
inspection (panel A) and also at a common scale (panel B) to facilitate cross-species
comparisons. Data are arranged by ascending β value where applicable.
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Fig. 32. Marmoset MSS summary. Consistent with the QTc–RR slopes (Fig. 31), the in-
dividual QTca correction provided the most efﬁcacious rate-dissociation. QTcV and
QTcF progressively reduced MSS as the β value increased (see text). The QTcB β
value (0.5) is greater than the mean QTca β value (0.446) and increased measurement
error relative to QTca, but was superior to the other generic methods.
100
120
140
160
180
200
-2 2 6 10 14 18 22
m
s
Hours
Veh
10 mg/kg
30 mg/kg
100 mg/kg
room entry
Fig. 30.Marmoset QTca summary. The individually rate-correctedQTca interval exhibited
dose proportional increases in both magnitude and duration. The peak increase (~30 ms)
was coincidentwith themoxiﬂoxacin Tmax. The rate-dependent raw QT variability noted
with vehicle treatment (Fig. 29) resolvedwith application of an individual rate-correction.
Data are from a single site employing morning dosing (n = 8).
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Fig. 29. Marmoset raw QT summary. The raw QT interval paralleled changes in the RR
interval with dose-dependent prolongation evident at all doses. The magnitude and
duration of moxiﬂoxacin-associated increase was well-correlated with TK. Data are
from a single site employing morning dosing (n = 8).
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Fig. 33. Impact of heart rate changes on marmoset QT/QTc. The raw QT exhibited the
expected rate-dependent changes which were effectively dissociated by the application
of the individual QTca and QTcB formulae which employed similar β values of 0.446 and
0.5, respectively. As evidenced by the associated MSS (Fig. 32) optimal rate-dissociation
was only achievedwith QTca. However, the generic application of QTcB conveys adequate
assay sensitivity in the absence of an individual rate-correction and is appropriate in this
species when an individual rate-correction is not feasible.
Table 5
Marmoset QTref summary. Values for slope and θ are mean values for all vehicle treat-
ments (n = 14). An RRref of 400 ms was used for QT raw and QTca calculations while
QTcV, QTcF, and QTcB calculations employed an RRref of 1000 ms (see text). Results are
summarized in Fig. 33.
Marmoset Slope θ ΔQTRef
(RRref − 20%)
QTRef ΔQTRef
(RRref 20%)
% ms ms ms %
QTraw 0.1762 74.5 −9.7 131 145 159 8.9
QTca 0.0080 144.6 −0.4 147 148 148 0.4
QTcV 0.0962 149.2 −7.8 226 245 265 7.3
QTcF 0.0735 168.1 −6.1 227 242 256 5.7
QTcB −0.0177 238.9 1.6 225 221 218 −1.6
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8.1. Introduction
The guinea pig is the most widely used species for cardiac safety as-
sessments in the early stages of preclinical development. It offers well
known ex vivo models such as the isolated papillary muscle, atria, per-
fused heart (Langendorff) andmyocytes. Thesemodels allow the detec-
tion and evaluation of inotropic and chronotropic properties of new
drug candidates as well as electrophysiological properties. Since the
ICH S7B guidelines were adopted, the predictive value of these ex vivo
models has been extensively studied. Validation studies in isolated
papillary muscles demonstrated good predictive value (sensitivity and
speciﬁcity) for agents that are known to block the hERG channel and
prolong the human QT interval (Hayashi et al., 2005). These data sug-
gest that action potential duration (APD) studies conducted in isolated
guinea pig cardiac tissues offer an alternative in early development
strategies when compared to rat cardiac tissues, the latter considered
inappropriate because of a lack of IKr current.
Some torsadogenic agents may fail to prolong APD in isolated
guinea pig ventricular preparations. The most illustrative case is
terfenadine, which failed to prolong APD in isolated guinea pig papil-
lary muscles because of a multiple ion channel blocking properties
(Hayashi et al., 2005). The isolated guinea pig ventricular myocyte
model was reported to be more sensitive for detection of APD prolon-
gation with compounds such as terfenadine or cisapride inhibiting
multiple ion channels (Terrar, Wilson, Graham, Bryant, & Heath,
2007). However, APD prolongation at low concentrations generally
remains minimal with these types of agents, and is reversed at higherconcentrations because of a shortening proﬁle due to sodium and/or
calcium channel activity (Davie et al., 2004). The latter also occurs
in isolated canine Purkinje ﬁbers (Champeroux et al., 2011). The guinea
pig Langendorff heart has also demonstrated human predictive value
for QTc prolongation with a large number of reference drugs
(Gerhardy, Scholtysik, Schaad, Haltiner, & Hess, 1998; Kurokawa et al.,
2008; Roche, Kijtawornrat, Hamlin, & Hamlin, 2005; Testai, Breschi,
Martinotti, & Calderone, 2007).
Of note, many of the guinea pig QT validation studies which
employed multiple compounds were conducted under spontaneously
beating conditions (Cheng & Incardona, 2009; Cheng, Incardona, &
McCullough, 2006; Guo, Dong, & Guthrie, 2009; Hamlin, Kijtawornrat,
Keene, Nakayama, Nakayama, Hamlin et al., 2004; Tabo et al., 2010).
The paced heart eliminates the need for QT rate-correction, and in that
regard, is ideal for the accurate assessment of QT interval changes. How-
ever, the imposition of a ﬁxed cycle length also renders the model in-
sensitive to possible test article-related changes in cardiac automaticity.
In the isolated paced guinea pig heart, QT prolongation has been
detected with multiple ion channel blockers such as terfenadine
(Pinney, Koller, Franz, & Woosley, 1995). Similarly, 8/8 positive and
0/4 negative reference compounds including terfenadinewere detected
in a paced in vivo anesthetized guinea pig heart (Kagstrom, Sjogren, &
Ericson, 2007; Tabo et al., 2007). In contrast to the aforementioned
models, typical in vivo anesthetized guinea pig studies are not paced
and are usually conducted under spontaneously beating conditions.
Of the two anesthetics most frequently employed, urethane and
halothane, the latter has been reported to induce sensitization to
hERG-mediated QT prolongation (Sakaguchi et al., 2005) due a reduc-
tion of repolarization reserve (Takahara et al., 2005). In contrast to anes-
thetized animal models, studies in conscious animals avoid the possible
pharmacological interference of anesthetics. Several telemetry studies
have demonstrated hERG-mediated QT prolongation in the conscious
guinea pig (Hess, Rey, Wanner, Steiner, & Clozel, 2007; Rajput, Singh, &
Sharma, 2010; Shiotani, Harada, Abe, Hamada, & Horii, 2007; Shiotani
et al., 2005). In most of these studies, the Bazett QT rate-correction
was performed to conform to previously cited studies conducted both
in anesthetized or conscious guinea pigs, and in spontaneously beating
Langendorff studies.
QT/RR relationships obtained in the paced Langendorff guinea pig
heart conﬁrm that the Bazett formula provided more effective
rate-dissociation than either the Fridericia or Van de Water formulae,
or parabolic, hyperbolic, or exponential models (Cheng et al., 2006).
The aforementioned drug effects, assessed as QTc, were typically
associated with large standard deviations such that statistical signiﬁ-
cance was generally achieved only around Tmax. Similar to other
preclinical species and man, application of an individual QT rate-
correction would be expected to reduce QTc variability and improve
the statistical power in the guinea pig (Holzgrefe, Cavero, Buchanan,
et al., 2007). The current data contrast the effectiveness of the generic
(QTcV, QTcF, and QTcB) and individual probabilistic rate-corrections
(QTca in conscious telemetered guinea pigs following treatment with
vehicle and moxiﬂoxacin (90 mg/kg, p.o.).
8.2. Methods
Summary data for 5 guinea pigs (0.98 ± 0.13 kg, 15.0 ±
0.7 months, 3 male, 2 female) from a single site (C) are presented.
See Appendix Section 2.1.5 for site-speciﬁc housing, data acquisition,
and treatment details.
8.3. Results
8.3.1. QT–RR analysis
8.3.1.1. QT–RR distributions. Mean QT and RR data after vehicle treat-
ment (n = 5) are presented in Fig. 35. RR and QT populations were
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Fig. 34. Guinea pig moxiﬂoxacin PK.
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(>2.5% b 97.5% quantiles) were 205 to 311 ms for RR (193 to
293 bpm) and 124 to 174 ms for QT.
8.3.1.2. Site concordance. The potential for systematic parameter
differences between test sites was not applicable as all data were
from a single site.
8.3.1.3. QT/QTc–RR slope analysis. The individual-animal QT/QTc–RR
slopes (Fig. 39) indicated that QTca performed optimally. In contrast,
the generic corrections resulted in no improvement in QTc measure-
ment error, compared to that obtained with the raw QT. Similarly,
QTca minimized (effectively eliminated) heterogeneity in the QTc–RR
slopes across all animals, whereas heterogeneity for the generic correc-
tions was similar to or increased relative to the raw QT–RR.
8.3.1.4. MSS summary. To further evaluate the performance of the QT
rate-corrections, individual linear QTc–RR regressions were performed
for all vehicle treatments and the means of the squared QTc–RR slopes
(MSS) were derived (Fig. 40). Assessed as the MSS, the QTcB correction
typically employed in guinea pig studies did not substantially reduce
QTc variabilitywhen compared to either QTcF or QTcV, despite a slightly
better mean slope reduction. The application of an individual probabi-
listic QT rate-correction effectively removed effects of heart rate, yield-
ing a stable QTca interval.
8.3.1.5. Impact of heart rate changes on QT/QTc. To examine the practical
impact of rate-correction performance on QTc, QTc was derived for
each rate-correction at RR intervals associated with 20% increases and
decreases from RRref (Fig. 41, Table 6). The raw QT exhibited the
expected rate-dependent changes which were effectively dissociated
only by the application of QTca, consistent with the steep raw QT–RR
slope and associated mean individual β value (0.786 ± 0.198) which
greatly exceeded those associated with the generic corrections. In all
cases, the excessive generic QTc measurement error virtually precludes
the possibility of an accurate test-article QT assessment and is consistent
with the low sensitivity previously reported in this species (Cheng et al.,
2006).
Table 6 dramatically highlights the potential impact of a physio-
logically inappropriate RRref in any QT rate-correction or normalization
calculation. At a cycle length of 260 ms, the raw QT in the guinea pig is
~150 ms and this can be conﬁrmed from direct ECG measurements.
When RRref is changed to 1000 ms (typical for all generic corrections),
the associated QTc increases to 540–550 ms (Table 6). The latter QTc
values cannot exist in vivo and cannot be physiologically conﬁrmed.
Moreover, any generic QTc calculation which employs a delta calcula-
tion (change from baseline, vehicle, or both) results in dramatically
ampliﬁed QTc values, rendering accurate repolarization assessment or
comparison to other studies virtually impossible.
8.3.2. Moxiﬂoxacin
8.3.2.1. Exposure and pharmacokinetics. Peak moxiﬂoxacin plasma levels
were reached with the ﬁrst 1 h post-dose and rapidly decreased
between 2 and 4 h post-dose. From 6 to 24 h the elimination of
moxiﬂoxacin was clearly slower suggesting a possible deep tissue
compartment. The half-life of the ﬁrst phase of elimination was
between 1 and 2 h while the second phase was clearly much longer.
Detailed compartmental modeling was not performed due to limited
sampling.
8.3.2.2. QT and RR effects. Figs. 36–38 depict the time courses for RR, QT,
and QTca intervals before and after the administration of vehicle or
moxiﬂoxacin (90 mg/kg, p.o.), excluding the dosing period (±20 min
of 0 h). Vehicle administration elicited no effect on RR, QT, or QTca in-
tervals with the exception of transient changes during dosing, cleaning,feeding, and light/dark transitions. Moxiﬂoxacin at 90 mg/kg induced a
rapid increase in QT and QTca intervals. The RR interval was increased
(20–40 ms) from ~3 to 17 h post-dose. Increases in the rawQT interval
(10–20 ms) paralleled changes in the RR interval and persisted through
~17 h post-dose. In contrast, moxiﬂoxacin elicited a short-lived in-
crease in QTca (10–12 ms) which recovered to baseline by 3 h
post-dose, consistent with the rapid plasma clearance of moxiﬂoxacin.
The concordance of the changes in QTca with the moxiﬂoxacin plasma
levels indicates that changes in the raw QT interval were poorly corre-
latedwith electrophysiological changes in repolarization andwere like-
ly related to a drug-mediated increase in cycle length, highlighting the
necessity of an accurate QT rate-correction.
8.4. Guinea pig summary
The current data conﬁrm thatmoxiﬂoxacin elicits QT prolongation in
guinea pigs, consistent with its hERG blocking properties. Moxiﬂoxacin-
associatedQTcaprolongationwas relatively short, persisting for approx-
imately 3 h post-dose, consistent with plasma exposures where
~70–80% of the drug concentration (AUC) was between 0 and 3 h
with peak concentrations observed at 1 h post dose. These pharmacoki-
netic data are very close to those published in other small species such
as mice and rats while much longer half-life elimination values (>7 h)
are reported in large species (dogs, cynomolgus monkeys, minipigs)
and human (Siefert et al., 1999).
Compared to the generic corrections, the QTca was the only
method which effectively dissociated the effects of heart rate from
the raw QT, reﬂected in the associated QTc/RR slopes which were
close to null. This is particularly important in the guinea pig since
this species exhibits the highest raw QT/RR slope among all common
preclinical species (Fig. 49). Although the Bazett formula has been
historically employed in guinea pig repolarization studies the current
results demonstrate that it is clearly insufﬁcient in terms of QTc–RR
slope correction and reduction in the associated QTc measurement
error. Indeed, due to the very steep raw QT–RR slope, the individual
rate correction coefﬁcient (β value) for the guinea pig was 0.79 ±
0.20. As illustrated in Figs. 39 and 40, the corresponding β values for
QTcF (0.33) and QTcB (0.5) do not effectively dissociate the effects
of heart rate. The impact of suboptimal rate-correction is readily
apparent in the current data where moxiﬂoxacin prolonged the RR
interval (20–40 ms for 17 h) with a concomitant and expected increase
in the raw QT interval. Application of QTcV, QTcF, and QTcB formulae
yielded treatment-associated QTc increases of 15–25 ms (data not
shown) which persisted for the duration of the RR effect. In contrast to
the generic assessments, the individual QTca indicated a 10–15 ms pro-
longation which persisted for approximately 3 h, yielding a treatment
effect which was tightly correlated with the moxiﬂoxacin PK/Tmax.
These observations highlight the serious and unacceptable risk of gener-
ating either false positive conclusionswhen heart rate slows, as occurred
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Fig. 36. Guinea pig RR summary. Compared to vehicle, moxiﬂoxacin (90 mg/kg)
prolonged the RR interval by ~10% (10–20 ms), with the effect persisting for ~17 h
post-dose. Data are from a single site (n = 5).
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compound induces tachycardia.
In the current multi-site study, the guinea pig exhibited the highest
rawQT–RR slope among the species studied. As such, it is not surprising
that this species also exhibited the largest inter-individual variability in
raw QT–RR slopes. Under these conditions, the application of ﬁxed
generic rate-corrections failed to improve the inter-individual QTc–RR
slope dispersions depicted in Fig. 39. In contrast, QTca reduced the
mean QTc–RR slope to −0.0039 ± 0.198, effectively and uniformly
dissociating the effects of rate across all subjects, evidenced by the
low associated SD (±0.198). At site C, historical QT datasets from typi-
cal guinea pig studies (n = 6) employing generic rate-corrections (data
not shown) have generally yielded minimal detectable differences of
>10 ms which were reduced to 3–4 ms with QTca. It is likely that
QTca stability in the guinea pig is related not only to a methodological
reduction of inter-individual QTc/RR variability but also to the tightly
constrained dynamic QT–RR range in this species (Fig. 35). The mean
QTca AUC centered on 1 h at Tmax and normalized to moxiﬂoxacin
exposure (0.0030 ± 0.0021 Δms%/μM) was slightly less than observed
in other species, but this slight decrease did not achieve signiﬁcance
(Fig. 51).
QT prolongation induced by IKr blockers in the guinea pig is
clearly smaller in terms of amplitude (not duration) than in other
species. Results achieved with moxiﬂoxacin or other hERG blockers
suggest that maximum effects on QT interval resulting from hERG
block ranges between 10 and 15 ms for most of drugs in conscious
guinea pigs versus 25–50 ms in beagle dogs or cynomolgus monkeys.
The truncated amplitude response to hERG-mediated IKr block could be
related to the prominent role of the IKs in guinea pig cardiac tissues
(Cheng & Incardona, 2009). IKs blockers elicited larger QT prolongation
than moxiﬂoxacin in the isolated perfused guinea pig heart (Ducroq et
al., 2010) The interspecies comparison of the normalized QT response
in relation to moxiﬂoxacin is consistent with this ﬁnding since the
electrophysiological proﬁle is close to that of a pure IKr blocker
(Champeroux et al., 2011) and the normalized response tomoxiﬂoxacin
was found to be the smallest among the species studied in this multisite
study.
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Fig. 35. Guinea pig QT–RR relationship. RR and QT populations (n = 5) were normally
distributed, and under control conditions (2.5%b>97.5% quantiles) ranged from 205 to
311 ms for RR (193 to 293 bpm), and from 124 to 174 ms for the raw QT. Similar data for
the dog are presented for comparison (RR range 440 to 1193 ms; raw QT 174 to 283 ms).
The guinea pig QT–RR relationship exhibited the steepest slope of all the current preclin-
ical species andwas also characterized by themost constrainedQT–RR range. Similar to all
other species, the guinea pig was also demonstrates rate-independent QT variability.100
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Fig. 37. Guinea pig raw QT summary. The raw QT interval prolonged in parallel with
the RR interval (Fig. 36). Data are from a single site (n = 5).
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Fig. 38. Guinea pig QTca summary. The application of QTca resolved apparent rate-
associated raw QT changes in the vehicle treated group, yielding a stable QTca baseline
of ~155 ms. Following administration of moxiﬂoxacin (90 mg/kg), QTca rapidly
prolonged by 10–12 ms, with the effect persisting for ~3 h. Importantly, dissociation of
the effects of rate on the raw QT interval (Fig. 37) conﬁrms the notion that the prolonged
increase in the raw QT following moxiﬂoxacin was largely a rate-driven effect where the
drug mediated repolarization delay persisted for ~3 h, consistent with the peak plasma
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Fig. 40. Guinea pig MSS summary. Consistent with the QTc–RR slopes (Fig. 39), the in-
dividual QTca rate-correction was the only efﬁcacious correction method. The lack of
efﬁcacy for the generic rate-corrections is consistent with QTca β value (0.786 ±
0.198) which greatly exceeded all generic β values. Given the uniquely steep QT–RR
relationship in the guinea pig, QTc values derived in the in the absence of an individual
rate-correction cannot accurately convey changes in repolarization in this species.
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Fig. 41. Impact of heart rate changes on guinea pig QT/QTc. The raw QT exhibited the
expected rate-dependent changes which were effectively dissociated only by the appli-
cation of an individual QTca rate-correction. As illustrated by the associated MSS-0.20
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Fig. 39. Guinea pig QT/QTc–RR slope summary. QTca yielded a nearly optimal QTc–RR
slope of−0.0039 ± 0.004. The mean QTca β value (0.786 ± 0.198) exceeded all of the
generic β values, reﬂected in the large, positive slopes for all of the generic rate-
corrections. Importantly, none of the generic rate-corrections reduced the QTmeasure-
ment error compared the raw QT values. As the guinea pig exhibited the highest QT–RR
slope, all other species employ the current scale for cross-species comparisons (Panels
B). Data are arranged by ascending β value where applicable.(Fig. 40), the use of any generic rate-correction is contraindicated in the guinea pig.Table 6
Guinea pig QTref summary. Values for slope and θ are mean values for all vehicle treat-
ments (n = 5). An RRref of 260 ms was used for QT raw and QTca calculations while
QTcV, QTcF, and QTcB calculations employed an RRref of 1000 ms (see text). Results
are graphically depicted in Fig. 41.
Guinea pig Slope θ ΔQTRef
(RRref − 20%)
QTRef ΔQTRef
(RRref 20%)
% ms ms ms %
QTraw 0.4492 34.8 −15.4 128 152 175 13.4
QTca −0.0039 155.3 0.1 154 154 154 −0.1
QTcV 0.4325 108.6 −16.0 455 541 628 13.8
QTcF 0.4182 129.3 −15.3 464 548 631 13.3
QTcB 0.3372 212.8 −12.3 483 550 617 10.99. Human
9.1. Introduction
Since the implementation of ICH E14 guidance in May 2005 virtu-
ally all new drugs in clinical development have been required to dem-
onstrate relative risk of inducing Torsades de Pointes (TdP), assessed
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Fig. 42. QT–RR relationship. Randomly selected QT–RR pairs (~4K each) from the
human (n = 57) and dog (n = 34) exhibit clear separation in the respective dynamic
QT–RR ranges. Both populations demonstrate profound rate-independent QT variabil-
ity with multiple raw QT values noted for each discrete RR. This fundamental property
of the QT interval was noted in all current species and requires a probabilistic approach
to maximize measurement accuracy (Holzgrefe et al., 2012).
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study. This reference trial is generally performed in healthy subjects
and includes both a positive (typically moxiﬂoxacin) and a negative
(placebo) control. TQT studies typically employ continuous 12-lead
ECG recordings (Holter devices), protocol-designed time points for
plasma drug/metabolite levels and ECG extractions, and an appropri-
ate number of subjects in a cross-over (n ~ 40–80) or parallel
(n ~ 150–200) study design (Yan, Zhang, Ng, & Dang, 2010). The pos-
itive control is required to demonstrate assay sensitivity, and statistical
models (typicallymixed effectmodels) are employed to reliably exclude
a baseline- and placebo-corrected threshold pharmacologic effect of
~5 ms (with upper conﬁdence interval excluding 10 ms) on the
rate-corrected QT interval at each time point. The detection of such
small effect requires that the QT interval prolongation be precisely
assessed.
Recent advances in fully-automated ECG measurement platforms
in conjunction with distribution-based QT rate-correction methodol-
ogy have enabled the reliable derivation and application of individual
QT–RR relationships to continuous ECG data obtained in the context
of a TQT study (Holzgrefe et al., 2012; Meyer et al., 2013). Importantly,
these technologies have enabled the parallel application of the
same analytical methods to the current preclinical and clinical
datasets.
9.2. Materials and methods
The current clinical data were derived from a TQT study which has
been extensively described elsewhere (Holzgrefe et al., 2012; Meyer
et al., 2013). All clinical ECG data (57 subjects)were analyzed at a single
site and were provided to the consortium at a default resolution of
5 min to enable cross-species comparisons.
9.3. Results
9.3.1. QT–RR analysis
9.3.1.1. QT–RR distributions. Mean QT and RR data after vehicle treat-
ment (n = 57) are presented in Fig. 42. RR and QT populations were
normally distributed and the dynamic ranges under control conditions
(2.5%b>97.5% quantiles) ranged from 644 to 1221 ms for RR and from
320 to 502 ms for the raw QT.
9.3.1.2. Site concordance. The potential for systematic parameter
differences between test sites was not applicable, as all data were
from a single site.
9.3.1.3. QT/QTc–RR slope analysis. Individual QT/QTc–RR slopes (Fig. 46)
demonstrated that QTcF and QTca fully dissociated the effects of rate
(0.020 ± 0.025 and 0.045 ± 0.026, respectively) whereas QTcB
resulted in a consistent over-correction and QTcV resulted in consistent
under-correction of the raw QT. The current results are consistent with
the notion that QTcF is generally well-suited in man as the ﬁxed β
value of 0.333 approximates the mean β value of the human popula-
tion (Tornoe et al., 2011). The slight superiority of QTcF over QTca
in the current dataset (Figs. 46–48) was likely due to the intra-
individual variability of the individual β value derivations across treat-
ment days, compared to the ﬁxed QTcF rate-correction coefﬁcient.
9.3.1.4. MSS summary. To further evaluate the performance of the QT
rate-corrections, individual linear QTc–RR regressions were performed
for all vehicle treatments and the means of the squared QTc–RR slopes
(MSS) were derived (Fig. 47). Consistent with QTc–RR slopes (Fig. 46),
the QTcF and QTca corrections were the most efﬁcacious methods in
man (MSS 0.0011 ± 0.0013 and 0.0026 ± 0.0023, respectively).9.3.1.5. Impact of heart rate changes on QT/QTc. To examine the practical
impact of rate-correction performance, QTc was derived for each
correction method at RR intervals associated with 20% increases and
decreases in heart rate (Fig. 48, Table 7). The raw QT exhibited the
expected rate-dependent changes which were most effectively dissoci-
ated by the application of QTcF and QTca corrections. As a consequence
of the low QT rate-dependence in man (Figs. 46 and 49), both QTcB
and QTcV could also be employed without exposing the analysis to
dramatic measurement errors.
9.3.2. Moxiﬂoxacin
9.3.2.1. Exposure and pharmacokinetics.Moxiﬂoxacin plasma concentra-
tions were collected once at 2 h post-dose and demonstrated a mean
exposure of 866 ± 498 ng/mL. The apparent lowmoxiﬂoxacin concen-
tration was likely due to the co-administration of moxiﬂoxacin with
food, which is known to decrease the rate of absorption (Florian,
Tornoe, Brundage, Parekh, & Garnett, 2011). The QTca increase follow-
ing moxiﬂoxacin was ~4 ms at 2 h and increased to ~12 ms at 4 h
post-dose, consistent with expected moxiﬂoxacin pharmacokinetics.
9.3.2.2. QT and RR effects. Time-course proﬁles for RR, raw QT, and
QTca after vehicle and moxiﬂoxacin administration are presented in
Figs. 43–45. Expected decreases in QT and RR occurred at protocol
scheduled time points for ECG extractions and meals. Expected
moxiﬂoxacin time-dependent increases in QTca were apparent
throughout the 24 hour ECG recording.
9.4. Human summary
The current human TQT data have been previously reported
(Holzgrefe et al., 2012; Meyer et al., 2013) and are provided herein
to allow direct comparison of the current preclinical results to man.
The mean QTca AUC centered on 1 h at Tmax and normalized to
moxiﬂoxacin exposure (0.0005 ± 0.0004 Δms%/μM) was similar to
that observed in all other species (Fig. 51) with the single exception
of the minipig (see Section 6.4).
9.5. Human ﬁgures
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Fig. 43. Human RR summary. The mean RR intervals are depicted for the placebo and
moxiﬂoxacin (400 mg) arms of a Thorough QT Study (n = 57). The excursions noted
during the ﬁrst 12 h represent postural changes before and after protocol-directed
ECG extractions where the patients were required to lie supine for 10 min prior to
the recording, or meals (4 h and 12 h), resulting in repeated changes in adrenergic
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Fig. 44. Human raw QT summary. The raw QT interval changed in parallel with the RR
interval (Fig. 43) where protocol-associated changes in adrenergic tone were clearly
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Fig. 46. Human QT/QTc–RR summary. The human QT–RR relationship is characterized
by a shallow slope (mean 0.1669 ± 0.03) such that all generic rate-corrections largely
dissociated the effects of rate. As has been well-documented, QTcF was well-suited to
this population while QTcB introduced an additional measurement error. Data are
scaled for within-species inspection (panel A) and also at a common scale (panel B)
to facilitate cross-species comparisons. Data are arranged by ascending β valueevident. Moxiﬂoxacin elicited an expected small increase in the raw QT interval.390
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Fig. 45. Human QTca summary. Application of QTca revealed a persistent moxiﬂoxacin-
related QTca increase of 10–14 ms which persisted for ~22 h post-dose, consistent
with the associated moxiﬂoxacin plasma levels in this study. These results conﬁrmed
TQT assay sensitivity as required by ICH E14 and have been previously reported in de-
tail (Holzgrefe et al., 2012; Meyer et al., 2013).where applicable.0.000
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Fig. 47. Human MSS summary. The human QT–RR relationship was similar to the dog
where both species exhibited low QT rate-dependence (Fig. 49). Given the low QT
rate-dependence, all rate-corrections yielded an adequate result. MSS is increased
with QTcB indicating that application of the higher β value (0.5) introduced an
over-correction as depicted in Figs. 46 and 48. Note the MSS scaling relative to the
cynomolgus monkey (Fig. 17).
Table 7
Human QTref summary. Values for slope and θ are mean values for all vehicle treat-
ments (n = 57). An RRref of 1000 ms was used for all calculations such that all derived
values where within the normal physiological range and can be veriﬁed in vivo. Results
are graphically summarized in Fig. 48.
Human Slope θ ΔQTRef
(RRref − 20%)
QTRef ΔQTRef
(RRref 20%)
% ms ms ms %
QTraw 0.1669 254.5 −7.9 388 421 455 7.3
QTca 0.0447 377.5 −2.1 413 422 431 2.1
QTcV 0.0800 341.8 −3.8 406 422 438 3.7
QTcF 0.0199 402.6 −0.9 418 422 426 0.9
QTcB −0.0602 483.4 2.8 435 423 411 −2.9
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Fig. 48. Impact of heart rate changes on human QT/QTc–RR. Due to similar β values and
consistent with the MSS (Fig. 47), QTca, QTcV, and QTcF effectively dissociated the ef-
fects of rate from the raw QT and yielded an acceptable result. QTcB under-corrected
the raw QT as RR decreased, and over-corrected as RR increased, introducing an other-
wise controllable error into the analysis.
Table 8
Raw QT slope descriptive statistics. Enumerated raw QT–RR slopes by species (Fig. 49).
Raw QT slope N Mean Mean SE Variance SD
Dog 34 0.0901 0.0041 0.0006 0.0240
Human 57 0.1669 0.0039 0.0009 0.0296
Marmoset 14 0.1762 0.0159 0.0035 0.0594
Minipig 12 0.2005 0.0182 0.0040 0.0630
Cynomolgus 37 0.3345 0.0147 0.0080 0.0897
Guinea pig 5 0.4492 0.0561 0.0157 0.1255
dog human marmoset minipig cyno guinea pig
0.1
0.3
0.5
0.7
0.9
1.1
B
et
a
QTcB
QTcF
Fig. 50. Individual probabilistic QT rate-correction beta values—distribution by species.
The intrinsic raw QT rate-dependence illustrated in Fig. 49 is reﬂected in the associated
β values obtained by probabilistic modeling of the individual off-treatment data
(Section 3.2). Importantly, the relationship of the individual β values to the ﬁxed
QTcB and QTcF rate-correction coefﬁcients (dotted lines) highlights the intrinsic
error encountered when these corrections are applied to either the cynomolgus
monkey or guinea pig. While QTcV is a linear model which does not employ a β
value, a ‘best ﬁt’ exponential model of the canine QTcV values yields a putative β
value of 0.273 and is provided for comparison. Data are ordered by ascending β
value; box plot presents mean, 5th, and 95th quantiles. See Table 9 for detail.
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Fig. 49. Raw QT slope—distribution by species. The mean slopes and distributions for
the individual raw QT–RR relationships demonstrate marked species-speciﬁcity. The
differential increase in the QT–RR slopes noted with the cynomolgus monkey and
guinea pig underscores profound and unique QT rate-dependence which is satisfacto-
ry addressed only by the application of an individual rate-correction. See Table 8 for
detail. Data are ordered by ascending slope; box plot presents mean, 5th, and 95th
quantiles.10.2. Beta value summary by speciesTable 9
Individual rate-correction beta values by species. The optimal rate-correction coefﬁ-
cients for the dog, human, marmoset, and minipig overlap with at least one of the
generic rate-correction formulae Fig. 50). In contrast, the uniquely steep QT–RR slopes
in the cynomolgus monkey and guinea pig render the application of any of the generic
rate-corrections mathematically inappropriate in these species. In the absence of an
individual rate-correction, the current β values merit consideration as ﬁxed correction
coefﬁcients (guinea pig excepted) due to the demographic diversity of the underlying
populations.
Beta N Mean Mean SE Variance SD
Dog 34 0.2729 0.0100 0.0034 0.0586
Human 57 0.2812 0.0068 0.0026 0.0511
Marmoset 14 0.4265 0.0299 0.0125 0.1118
Minipig 12 0.4279 0.0335 0.0134 0.1159
Cynomolgus 37 0.6818 0.0270 0.0269 0.1641
Guinea pig 5 0.7861 0.0890 0.0396 0.1989
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Fig. 51. Normalized moxiﬂoxacin response at Tmax. Cross-species sensitivity to
moxiﬂoxacin was assessed as the normalized QTca AUC per μM moxiﬂoxacin
(Section 3.3.1) derived for 1 h, centered on the respective Tmax for each species. The
latter step was necessary to enable an unweighted QTca comparison which included
the guinea pig, a species with very short effect duration (see Section 8.3.2). With the
single exception of the minipig, there were no signiﬁcant differences in the normalized
moxiﬂoxacin QTca response. Protracted food effects are known to confound absorption
in the minipig and are consistent with the large standard deviation associated with this
species (see Section 6.4). Importantly, the current results demonstrate the general con-
servation of hERG-mediated QT prolongation across all species and indicate that all
preclinical repolarization results are readily and directly transferable to man. Data
are mean ± SD and are ordered as depicted in Fig. 50.11. Discussion
Given the recognized lack of concordance between non-clinical
and clinical repolarization assays, the elucidation of any possible
underlying mechanistic basis for the current lack of agreement in
model outcomes remains crucial for both the drug development and
regulatory communities (Pugsley, Authier, & Curtis, 2008). The primary
goal of the current report is the disclosure an unprecedented body of
preclinical data (numbers of species and subjects) collected from a
consortium of pharmaceutical research sites for the general use and
scrutiny of the scientiﬁc community. All data analyses were prospec-
tively designed to explore the current lack of preclinical–clinical concor-
dance with in vivo repolarization (QT) assays. The consortium results
characterize, for the ﬁrst time, an important gap in our understanding
of the discrepancies between the in vivo assays used to detect drug-
induced QT liabilities in non-clinical species and therefore the difﬁculty,
or even impossibility, of extrapolating these non-clinical QT data to
man.
As the primary purpose of the current report is the public disclosure
of consortium data, detailed reviews of the point-by-point results are
beyond the current scope and will be the subject of future communica-
tions. The current discussion is thus restricted to those observations
which directly address prominent regulatory concerns, and which
may offer a possible unifying scientiﬁc rationale for in vivo QT assess-
ments. Chief among these are the impact of unique non-overlapping
dynamic QT–RR ranges across species and, to our knowledge, the ﬁrst
systematic application of the mean squared slope (MSS; Section 2.3)
to objectively assess the efﬁcacy of all common QT rate-correction
methods across all common non-rodent species, including man. To
address the aforementioned goals, moxiﬂoxacin was employed as a
single reference agent at overlapping doses in all species, enabling the
objective characterization of both the cross-species and human transla-
tion of the various in vivo repolarization models.The years subsequent to the adoption of the ICH S7B and E14 guid-
ances have witnessed an ever increasing emphasis on the accurate
and early detection of repolarization liabilities. To this end, substantial
effort has been devoted to the characterization of in vivo preclinical
repolarizationmodels and their translation tomanwhere the outcome,
to date, has been very unsatisfactory. Despite a rapidly expanding body
of preclinical work and the expenditure of billions of dollars to fulﬁll
regulatory requirements (partially reviewed in this report), current
regulatory cardiovascular safety assessment still relies principally on
clinical results (Anonymous, 2008) Groups have emerged assembling
people from the pharmaceutical industry, together with colleagues
from regulatory agencies, to decipher the nature of preclinical–clinical
disconcordance and identify solutions for the problem at hand. For
example, ILSI-HESI recently initiated The HESI Cardiovascular Pro-
arrhythmia Models Project (Trepakova, Koerner, Pettit, Valentin, &
Committee, 2009) to examine the preclinical predictability of repolari-
zation delay to man for 71 drugs which had been submitted for regula-
tory approval where all reviewed drugs included TQT results as a
reference standard. In this comparison, the translation of preclinical in
vivo ECG (QT) studies was “moderate, at best” (Anonymous, 2012)
and it was concluded that although “concordance estimates and conﬁ-
dence in non-clinical to clinical translation has improved recently”, pre-
clinical studies were necessary and should be improved by “providing
higher quality submission data addressing 1) selection of test doses or
concentrations in submission; 2) experimental design and data
analysis; 3) reviewing sample size; and 4) knowing assay sensitivity
and adequate use of positive controls”. While implementation of these
recommendations may offer some improvement, they fail to address
the underlying basis for the observed lack of agreement.
In the context of the consortium results, the aforementioned lack
of concordance is an expected outcome. Moreover, in the absence of
proactive research and model development by the drug-discovery
community, or revised regulatory guidance, sponsors have been free
to invoke multiple in vivo repolarizationmodels. Notably, thesemodels
have typically employed QT rate-correction procedures which were
based on historical precedent rather than relevant and objective scien-
tiﬁc observations. The general lack of recognition of the species-speciﬁc
nature of QT–RR relationships and the unfounded application of QT
rate-correction formulae which were largely derived from human
data, have certainly contributed to the current lack of concordance.
The consortium results conﬁrm that across all species, the QT
interval is characterized not only by rate-dependent variability, but
alsomarked rate-independent variabilitywheremultiple rawQT values
are associated to each discrete RR interval. This so-called probabilistic
nature (Holzgrefe, Cavero, Gleason,Warner, et al., 2007) of the QT inter-
val represents an additional and important source of otherwise control-
lable error. Primary endpoints for the consortium analysis included
characterization of the individual QT–RR relationships and the objective
assessment of the efﬁcacy of the generic QT rate-corrections for each
species, compared to an individual probabilistic QTca.
Although the individual nature of the QT–RR relationship has been
well-characterized in man (Batchvarov & Malik, 2002; Batchvarov
et al., 2002), the current data present the ﬁrst cross-species preclinical
conﬁrmation of this observation. Moreover, while the use of individual
QT rate-corrections is recognized as a best practice in the nonhuman
primate (Leishman et al., 2012), the use of generic QT rate-corrections
remains commonplace, and may represent the only alternative in
study designs where sufﬁcient high resolution baseline data are not
available, such as a repeat-dose toxicology study. Irrespective of the
underlying reasons, the current results highlight the intrinsic computa-
tional error thatmay be encounteredwhen rate-corrections are applied
without consideration of the species-speciﬁc QT–RR relationships.
The current results demonstrate that the QT–RR dynamic ranges
(Figs. 5, 12, 20, 27, 35, and 42) varied distinctly by species where
dog and human exhibited the lowest QT rate-dependence (Fig. 49)
followed by the minipig and marmoset. Rate dependencies for these
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and guinea pig. The associated QT and RR vehicle data were modeled
(Section 3.2) to obtain individual probabilistic rate-correction coefﬁ-
cients (β values) which are summarized in Fig. 50. As expected, β
values increased with increasing rate-dependence where the highest
values were again noted for the cynomolgus monkey and guinea pig
(Table 9). These summary data clearly illustrate the potential impact
of species-speciﬁc QT–RR relationships on the efﬁcacy of the generic
(ﬁxed) rate-corrections. It is serendipitous that most of the early in
vivo safety pharmacology studies were performed in canine models
(Hanson et al., 2006) where QT rate-dependence is extremely low,
and broadly similar to man. The very low intrinsic QT rate-
dependence in these species minimizes the need for an effective
rate-correction procedure to obtain a reliable estimate for a possible
change in QT. As illustrated in Fig. 9, QTca, QTcV, and QTcF conferred
only marginal improvements in QTc–RR slope reduction in the dog
compared to the raw QT, while QTcB introduced an increase in mea-
surement error (Figs. 9 and 10). The increased error with QTcB is
expected and is wholly consistent with the application of the ﬁxed
QTcB β value of 0.5, nearly 2-fold greater than the optimal canine β
value of 0.273.
It is remarkable that most rigorous exploratory efforts on QT
assessment have occurred in man, as the ultimate ‘safety’ species is
characterized by very low intrinsic QT rate-dependence where QT
interval measurement precision and probabilistic uncertainty likely
account for a greater proportion of error in the QTc estimate than
any particular rate-correction method (Fig. 47). When applied to
human data, the currentmethods and analyses provide a clear scientiﬁc
rationale which conﬁrms the empirical notion that, among the ﬁxed
corrections, QTcF performs optimally in man (Husser & Hindricks,
2010; Chiladakis et al., 2010).
While the aforementioned sources of QTc error and the associated
impact on interpretation also extend to the dog, where QT rate-
dependence is less than in man, such is not always the case. As illus-
trated in Figs. 49 and 50, the uniquely steep QT–RR relationships in
the cynomolgus monkey and guinea pig yielded optimal β values
much greater than 0.5 such that all generic rate-corrections were
ineffective (Figs. 17 and 40) in dissociating the effects of rate in
these species. The potential consequences of an inappropriate rate-
correction are clearly depicted in the guinea pig where moxiﬂoxacin
induced a sustained increase (~17 h) in the RR interval with a corre-
sponding increase in the rawQT interval. QTcF indicated amoxiﬂoxacin
effect (10–20 ms, data not shown) where duration paralleled the
increase in RR (17 h) due to ineffective rate dissociation. In contrast,
QTca indicated a repolarization effect which persisted for ~3 h, tempo-
rally consistent with the PK proﬁle. The guinea pig also provides a
dramatic illustration of the potential impact of physiologically inappro-
priate reference cycle lengths in any QT rate-correction calculation.
The initial rate-correction formulae (QTcB and QTcF) were derived
from human data and reasonably normalized QTc to a cycle length of
1000 ms (60 bpm), a typical resting heart rate in man. The Van de
Water correction (QTcV), derived from canine observations, followed
a similar rationale and also used 1000 ms as the reference cycle
length (Van de Water et al., 1989). In both cases, the calculated QTc
values could be directly veriﬁed in vivo as the reference cycle length
was within the normal physiological range. The situation is much dif-
ferent for some other preclinical species, in particular, the cynomolgus
monkey, marmoset, and guinea pig where the normal cycle lengths
exclude 1000 ms (Figs. 12, 27, and 35). The generic corrections have
typically been implemented as historically presented and have typically
failed to address the often dramatic differences in base cycle length
in some preclinical models. For the guinea pig, when the raw QT
(~150 ms) is adjusted to a cycle length of 1000 ms, the associated QTc
value increases to ~540 ms (Table 6). Marked QTc offsets are also
observed for the cynomolgus monkey (Table 3) and marmoset
(Table 5)with a default reference cycle length of 1000 ms. Investigatorshave dealt with these types of obvious discordance by resorting to delta
(change from baseline) or double delta (baseline-adjusted change from
placebo) QTc expressions where the underlying calculated QTc values
are masked, with only the difference presented, either in ms or more
commonly as a percentage change from either baseline or vehicle
(Ando et al., 2005; Sasaki et al., 2005; Taylor & Gleason, 2010). Absolute
values have also appeared in the public domain,most commonly for the
cynomolgus monkey where QTc values of >500 ms have been
presentedwithout comment (Lynch et al., 2008). The latter case reﬂects
a combination of an ineffective generic rate-correction (QTcF), drug-
induced change in heart rate, and an inappropriate reference cycle
length and highlights the intrinsic difﬁculty of reconciling results
between sites, or from a regulatory perspective, across submissions. In
the absence of guidance which standardizes QTc data presentation
(ms or %), reference cycle length, and rate-correction coefﬁcients, the
current lack of concordance of preclinical data with clinical outcomes
remains a virtual certainty. Therefore, it is in the interest of the drug
development and regulatory communities to standardize these assays
as needed, and implement the appropriate modiﬁcations to their
cardiosafety, pharmacology, and toxicity protocols.
As noted in the statistical overview, for QT rate-correction efﬁcacy
it only matters that the new rate-corrected value, QTc, shows less var-
iability which is not related to the effects under investigation, i.e. is
more reliable, than the raw QT and represents a biologically valid
concept for the detection of possible repolarization effects. In this
regard, and stipulating that the goal of heart rate-correction is to
reduce measurement variability, the optimal model for rate-correction
can be objectively assessed as that model which yields smallest overall
within subject variability under physiological conditions. As described
in Section 2.3, this is accomplished in the current study by employing
a comparison of the mean squared QTc–RR slopes (MSS) obtained for
each correction method (Tornoe et al., 2011). The current results
conﬁrm the probabilistic nature of the rawQT interval across all species,
including man. When this controllable source of error was considered,
then the associated individual QTca yielded a near optimal QT rate-
correction in all species. As illustrated in Figs. 49 and 50, the consortium
results describe species-speciﬁc QT–RR domains, which are associated
with varying ranges of optimal β values. The potential efﬁcacy of any
possible generic or individual rate-correction coefﬁcient, regardless of
derivation, can be prospectively determined by comparing the overlap
of the putative β value to the established optimal range for a speciﬁc
species. Given the widespread use of ﬁxed generic rate-corrections, in
conjunction with unrecognized probabilistic QT variability, the current
lack of preclinical translation toman is not only expected, but more im-
portantly, preventable. Indeed, while preclinical studies have employed
models with limited numbers of subjects and widely divergent QT–RR
relationships, studies in man have beneﬁted from large study popula-
tions (Florian et al., 2011) where intrinsic QT rate-dependence is very
low. Employing a common analytical scheme, the current data present
a parallel QT–RR comparison across all species and clearly demonstrate
that preclinical variability can be reduced to the same extent as in man
when the species-speciﬁc QT–RR domains are considered in the rate-
correction model.
Assays conducted across diverse platformsmust be referenced to a
common gold standard to accurately assess translation (Meyer et al.,
2013). For repolarization studies, moxiﬂoxacin is the most common
clinical reference agent andwas thus used to benchmark all current pre-
clinical results. As the current studies were conducted across multiple
sites and species, exact moxiﬂoxacin doses varied (3–100 mg/kg), but
in all cases, bracketed the expected therapeutic exposure in man after
a single 400 mg dose. Importantly, the plasma levels of moxiﬂoxacin
were linearly scaled over the current dose ranges (data not shown)
such that effective plasma concentrations, expressed as μM per mg/kg,
were constant within a given species and could be determined for all
studies. In three species (guinea pig, minipig, andman) plasma concen-
trations were measured during the conduct of the consortium studies.
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each species, the moxiﬂoxacin effect was quantiﬁed as the QTca AUC
for 1 h centered on Tmax. A restricted AUC window was required to
enable direct comparison of variable PK-driven response durations,
which ranged from ≤2 h to ≥24 h. In all cases QTca was expressed as
the individual change from the time-matched vehicle and the AUC
then derived as the % change to create a normalized response variable
which accounted for the large differences in absolute QTca values. The
QTca AUC was then further normalized as the change per μM
moxiﬂoxacin, which allowed the integration of all responses at all
doses within a species into a unitary response estimate. As clearly
evidenced in Fig. 51, the normalized QTca-moxiﬂoxacin responses
were similarly conserved across all species, including man. The minipig
response was signiﬁcantly higher than with the other species, but this
observation was based on a limited number of subjects where a food-
effect may have affected moxiﬂoxacin exposures (see text). These
unique data provide the ﬁrst unambiguous evidence that all preclinical
in vivo repolarization assays, when accurately modeled and evaluated,
yield results that are consistent with the conservation of moxiﬂoxacin-
associated QT prolongation across all common preclinical species, and
that these results are directly transferable, not only across species, but
also to man.
A biomarker is deﬁned as ‘a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic
intervention’ (Anonymous, 2001). It may also be more simply deﬁned
as variable that is a surrogate for the variable of primary interest
(Pugsley et al., 2008). In the case of integrated cardiovascular risk
assessment, QTc in its various forms serves as an imperfect biomarker
for an increased risk of Torsades de Pointes and as primary surrogate
endpoint for repolarization delay. The current data provide several
speciﬁc observations that support QTca as a novel and accurate bio-
marker for repolarization delay: 1) as previously noted, increases in
QTca corresponded in a linear fashion to moxiﬂoxacin plasma levels
across all species and thus described a species-independentmoxiﬂoxacin
PK/PD relationship, 2) inspection of the vehicle data for all species
demonstrates the expected changes in RR and raw QT intervals as a
function of experimental interventions (dosing and handling), and
where applicable diurnal effects were noted. In all cases, QTca resolved
rate-associated changes in the raw QT, yielding a stable surrogate for
repolarization change while accurately conserving the minor dark
photoperiod QTca increases expected in those species with marked
nocturnal decreases in activity and body temperature, and, 3) the
underlying probabilistic QT analysis detected a signiﬁcant difference
in the slopes of the QT–RR relationships in the cynomolgus monkey as
a function of source where animals of Mauritius and Chinese origin dif-
fered signiﬁcantly. The latter novel ﬁnding further reduces controllable
error in primate studies where a ﬁxed rate-correction remains the only
option. Importantly, this origin difference iswholly consistentwith pre-
vious reports, which have demonstrated clear source-speciﬁc genotypic
differences in the cynomolgus monkey for a multiplicity of biologic
endpoints (Ebeling et al., 2011).
In the current report, the consortium presents high-resolution
descriptive ECG data for all non-rodent preclinical species where
the dog and cynomolgus monkey are of particular interest as the
observations are based on very large and diverse populations and thus
may provide useful reference ranges for the most commonly used
cardiosafety species. Of primary interest to the drug-development com-
munity, uniform preclinical sensitivity to detect a repolarization delay
with accurate and direct human translation has been conﬁrmed across
all major non-rodent species establishing, for the ﬁrst time, the requi-
site preclinical sensitivity to replicate and ultimately supplant the
need for a TQT study. Broader adoption and implementation of the con-
sortium analytical methods offers the potential to reduce the number of
preclinical animal studies, improve human safety, and dramatically
streamline and improve the drug-development process.Appendix 1
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1.3. Individual probabilistic QT rate-correction: step by step procedure
1.3.1. Introduction
Probabilistic QT rate-correction is a robust method; however, it
requires that some experimental and technical conditions are met for
application without risk of bias. The generic QT correction methods
are based on more or less complex single formulae that are usually
directly applied to QT–RR pairs. On the other hand, the probabilistic
method involves a two-step procedure. The ﬁrst step calculates the
baseline slope of the individual QT/RR relationship (β) for each subject
from pretreatment or vehicle data (18–24 h). The second step consists
of applying an individual QT rate-correction formula including the
appropriate individual β value for each subject to time matched data.
One of the main issues met by the potential users is the assignment of
10 ms RR bins to the baseline data for derivation of the QT/RR relation-
ships. Another important issue is the fact that this method requires
inclusion of a large datasets for accurate derivation the individual
QT/RR relationships and calculations of mean post-dose QTc values.
Due to these requirements, QT and RR intervals must be collected
using software that automatically and accurately locates the end of
the T-wave. This raises important issues about the quality control of
the T-wave location for large datasets (100–200K beats) and the level
of acceptance for the error rate of end of T wave location. This section
Fig. A1. Typical QT/RR relationship in a cynomolgus monkey recorded during a
treatment-free period. Mean QT/RR values were calculated by 10 ms RR increment.
Only those 10 ms RR increments containing≥500 pairs were selected. This graph also de-
picts the density of QT/RR pairs,with red areas depicting the highest proportion (50% of all
QT/RR pairs). The probabilistic QT/RR relationship crosses the middle of the areas
exhibiting the highest density giving it a sinuous aspect. Note the two gravity centers
due the very large amplitude of QT–RR changes between night and daylight periods.
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experience of our multisite group in terms of conditions of use
depending on species.
1.3.2. Step 1: calculation of the slope (β) of individual QT/RR relationship
All species, including humans, exhibit nycthemeral variations in
heart rate. Consequently, the slope (β) of QT/RR relationship must
be determined over an entire nycthemeral cycle, i.e. a 24-hour period.
This precaution allows derivation of the slope over the full RR interval
range typically encountered under physiological control conditions. It
should be mentioned that drug-induced changes in RR interval rarely
exceed this range of physiological variation. Indeed, collection of data
during the night period allows deﬁnition of QT values for long RR
levels while the daylight period reciprocally provides QT values for
shorter RR intervals, especially during period of high motor activity.
For instance, data recorded during feeding or room maintenance are
essential in beagle dogs for capturing QT/RR data corresponding to
high heart rates. This is particularly important in the dog since the
QT/RR relationship exhibits a marked inﬂection of the curvature for
long RR intervals. Consequently, the most convenient methods for
enabling such recordings are the telemetry technique in conscious
animals and the Holter (or an equivalent telemetric) method in
humans.
The individual QT/RR slopes must be determined under treatment-
free conditions. All labs in our multisite working group systematically
derived the β values for each subject before a new study period over
an 18–24 h period. When animals were reused for several successive
studies, this allows comparison of the stability of QT/RR relationships
between successive studies. As has been shown in man (Batchvarov
et al., 2002), our general conclusion is that the QT/RR slope is stable
over time period across all current preclinical species.
Calculation of the QT/RR slope must be automated. The ﬁrst step of
the algorithm is to sort the QT/RR pairs according to RR values by
10 ms RR increments: e.g. 200–210 and 210–220. The second step
consists in calculation of the mean QT and RR values for each 10 ms
RR increment.
EmployingMicrosoft Excel for post hoc data analysis, 10 ms RR bins
may be readily obtained employing the Excel Roundup function. For
data expressed in ms, Eq. (A1) assigns all RR values to the ascending
10 ms bin associated with native RR value:
¼ ROUNDUP RRraw=1000ð Þ;2ð Þ  1000: ðA1Þ
The equation converts the RRraw ms value to decimal seconds,
rounds this value up to 2 signiﬁcant digits, and then converts the
rounded value to the associated RR bin in ms. In practice, Eq. (A1) is
copied through the entire data array in a separate column. The Excel
PivotTable function can then be used to query the dataset by 10 ms
RR bin to generate the associated mean raw QT and RR pairs by sub-
ject by RR bin.
QT and RR values derived from a mean calculation obtained from a
pair number less than 250 for dogs and humans and less than 500 for
the other species must be excluded. These minimum numbers of pairs
have been demonstrated as sufﬁcient to avoid the possible bias due
the QT hysteresis, short term QT interval variability triggered by
autonomic nervous system changes and intrinsic rate-independent
variability (Holzgrefe, Cavero, Buchanan, et al., 2007).
The calculation of mean QT and RR values for each 10 ms RR incre-
ment can be derived from each beat (beat to beat analysis) or from
mean QT–RR values (RR bin method) derived from a short recording
period. In that latter case, 10 s ECG segment can be used for calculation
of individual mean QT/RR values over the whole 24-h period. This
allows reducing the total numbers of pairs from more than 100K in
beagle dogs to 8640 pairs of 10 s for a 24-h period. This binningmethod
provides similar slope values to those obtained with beat-to-beat anal-
ysis (Holzgrefe, Cavero, & Gleason, 2007). Nevertheless, the number ofbeats for each10 s segment should be estimated to ensure that themin-
imum beat requirement (250–500 depending on species) is fulﬁlled
during the calculation of mean QT–RR values for each 10 ms RR incre-
ment used for building the QT/RR relationship (Fig. A1).
Once these mean QT–RR values per 10 ms RR increment have
been obtained, the next step consists in a log–log transformation to
linearize possible curvilinear raw QT–RR relationships (Fig. A2). In
dogs, this linearization may not be fully achieved because the QT/RR
relationship curvature is bimodal. Indeed, in this species, the slope
of QT/RR relationship is clearly greater for low RR values than for
high RR levels. Despite this bimodality, the log–log transformation is
sufﬁcient to allow application of a simple linear model for calculation
of a mean slope. The QT/RR slope (β) is then determined from a sim-
ple linear regression analysis from the log–log transformed data. No
differential weighting is applied since the regression analysis is
performed from data calculated at regular RR intervals (10 ms). Ex-
treme QT–RR values must have the same weight in the slope calcula-
tion as the mid-range values even if though the latter are derived
from a larger number of beats. The probabilistic nature of the QT in-
terval stipulates that a minimum number of beats must be present
to accurately locate the mean of the associated raw QT distribution.
Once this minimum number has been satisﬁed, differential weighting
has no further impact (Holzgrefe, Cavero, & Gleason, 2007).
1.4. Step 2: calculation of QTca values
QT rate-correction is achieved by application of formula (A2) to
time matched data collected during all treatment phases
QTca ¼ QTraw= RRraw=RRrefð Þβ ðA2Þ
where RRref value is a ﬁxed value depending on species (see species
chapter) and corresponds to a physiological mid-range RR value.
When applied to the treatment-free QT and RR data, application of
this formula produces a QTca/RR relationship with a slope close to
null (Fig. A3), conﬁrming the effective dissociation of any rate-
dependence.
This formula can be applied to individual uncorrected QT and RR
values (QTraw, RRraw) in the case of beat-to-beat analysis or to
mean raw QT and raw RR values derived from speciﬁed ECG
Fig. A4. Time course of QTca changes versus QTraw (dot line) and heart rate (HR) dur-
ing the treatment free period (same animal as Fig. A1). QTca values are globally inde-
pendent from RR interval changes.
Fig. A2. Log–log transformation of the QT/RR relationship (same animal as Fig. A1) and
slope (beta) calculation derived from linear regression.
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calculated for a ﬁxed time point (e.g. 1 h post-dose) must also satisfy
the minimum beat requirement as deﬁned in step 1, i.e. 250–500 beats
depending on the species, in order to fulﬁll the principles of the proba-
bilistic method and minimize intrinsic rate-independent QT variability.
Instead of counting a prespeciﬁed number of beats, an interval centered
on the time points of interest (typically 5–60 min) is usually employed
for time-matched data. For instance, theminimum reporting duration is
usually not less than 5 min in beagle dogs. Taking into account a mini-
mum sustained heart rate of 50 bpm in this species, a ﬁxed 5 min peri-
od includes at least 250 beats (i.e. 5 min × 50 bpm) in the associated
QTca value, with correspondingly higher numbers of beats when heart
rate is >50 bpm.
When applied to time-matched data, QTca values become fully dis-
sociated from short term changes in heart rate. This is particularly evi-
dent in cynomolgus monkeys due to a pronounced nycthemeral cycle
for both for QT and RR changes (Fig. A4). It should be mentioned that
the probabilistic method does not mask the inﬂuence of the autonomic
nervous system on the QTca interval in the presence of large RR interval
changes. Indeed, the sympathetic nervous system is known to shorten
the QT interval independently from heart rate through a direct action
on the action potential duration in ventricles. This explains why QTca
shortening can be still observed during short episodes of sympathetic
activation (see t = 1 h (room entrance) or during the morning period,Fig. A3. QTca/RR relationship (same animal as Fig. A1). The slope of the QTca/RR rela-
tionship approaches zero.Fig. A4). The same phenomenon can be observed during periods of
blood sampling (Champeroux et al., 2011).
1.5. Quality of T-end adjudication
Since the probabilistic method requires the analysis of large QT/RR
datasets (100–200K pairs), adjudication of T-end must be automated.
This is certainly a critical issue when using the probabilistic method,
and all methods requiring analysis of a large number of beats. Even
as software analysis packages become more and more successful,
the quality of ECG waveforms and the location of ﬁduciary marks
must be carefully checked. Analytical efﬁciency is dependent on sev-
eral factors including ECG signal quality and also changes in T wave
morphology as a consequence of the period of the day, the heart
rate, or possible drug effects (Meyer et al., 2013).
Regarding the ECG signal quality, the best quality is achieved with
epicardial placement of the electrodes. With subcutaneous ECG elec-
trodes the ECG signal, especially in the cyno, is often noisy, exhibiting
an unstable isoelectric baseline that complicates reliable automated
T-wave determination (Holzgrefe, Cavero, Gleason, Warner, et al.,
2007). However, with the advent of pattern recognition analysis, sub-
cutaneous ECG electrodes have been used successfully in all preclini-
cal species. Surface ECG electrodes are generally used in man and
similar technology is typically employed in jacketed external teleme-
try (JET).
Regardless of the ECG electrode placement method or the computer
software efﬁciency, the reliability of the T-end locationmust be veriﬁed.
Since the amount of data is large (e.g. more than 100K beats per 24 h in
beagle dogs), a sampling method is required. In the absence of pattern
recognition analysis, the T-end adjudication error rate is estimated
by checking proscribed numbers of beats distributed randomly over
every hour of a recording period. Veriﬁcation over the entire 24 h peri-
od is essential as morphological changes may occur depending on the
period of day, heart rate, and/or the presence of drug.
If absent pattern recognition (100% veriﬁcation), the maximum
acceptable T-end error rate should be ≤10%. Indeed, since the proba-
bilistic method consists in the calculation of mean QTca values de-
rived from extremely large QT/RR samples, an error rate b10% does
not introduce a signiﬁcant bias in the ﬁnal QTca value.
Finally, visualization of the shape of the beat-to-beat QT/RR rela-
tionship (clouds) is often very informative regarding the quality of
the T-end declarations. Disruptions in the QT/RR relationship within
a limited RR interval range (Fig. A5) can generally be traced to aber-
rant T-end adjudications.
Fig. A5. In this example taken from data collected in a beagle dog (treatment free
period), a separate data distribution is noted for extremely short RR values (arrow)
disrupting the QT/RR relation within this RR range. Veriﬁcation of the ECG waveforms
revealed incorrect T-end declarations for this RR interval range.
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The application of QT rate-correction by the probabilistic method
requires a fully automated procedure for QTca calculations and an au-
tomated process for T-end measurement. Although the probabilistic
method is very robust, its application involves a comprehensive and
proper use of computer software and veriﬁcation of the T-end adjudi-
cation. The latter can be greatly enhanced by the use of fully automat-
ed pattern recognition analysis (Meyer et al., 2013).
2.1. Site methods
2.1.1. Canine — sites A, B, C, E, and G
2.1.1.1. Animal preparation. Purpose-bred beagle dogs (Canis lupus
familiaris) from local suppliers were used at each site. Animal ages
ranged from 9 to 22 months for sites B and C, from 25 to 60 months
for sites A and E, and 8.6 to 10.6 months for site G; body weight
ranges across the sites averaged from 9 to 12 kg. Equal numbers of
males and females (3 or 4 per sex) were used at sites A, B, C, and E;
8 males were used at site G.
Animals were single-housed during testing in stainless steel cages
or pens, or stalls in compliance with all locally applicable regulatory
requirements for animal health and welfare. Animal room environ-
ments were maintained at industry-standard ranges for room tem-
perature, relative humidity, and air changes; 12/12 hour light/dark
cycles were employed (6 p.m. to 6 a.m. or 7 p.m. to 7 a.m.). Water
was available ad libitum. On dosing days, certiﬁed canine diets were
offered in the afternoon, 4 to 5 h after dosing for sites A, B, E and G.
For site C, food was offered in the morning at least 6 h prior to dosing.
On non-dosing days, food was offered per laboratory standard
procedures.
2.1.1.2. Drug preparation and PK analysis. Moxiﬂoxacin HCl or vehicle
was administered orally according to the following experimental de-
signs. Site A) 10 and 30 mg/kg to 4 animals per sex via gavage in 0.5%
aqueous methyl cellulose (2 ml/kg) in a parallel design with vehicle
administration 48 h prior to each dose of moxiﬂoxacin; B) 3, 10,
and 30 mg/kg to 3 animals per sex via gavage in 0.5% aqueous methyl
cellulose (2 ml/kg) in a cross over design; Site C) 90 mg/kg to 3 ani-
mals per sex via gavage in water (5 ml/kg) in a cross over design;
site E) 3, 10, and 30 mg/kg via gelatin capsule (Type 10.30) to 3 ani-
mals per sex in a cross over design; and G) 10, 30, and 90 mg/kg to 8male animals by gavage in 0.5% aqueous methyl cellulose in a cross
over design. Prestudy telemetry test sessions (18 to 24 h in duration)
were performed within 2 weeks prior to the dosing phase of each
study for evaluation of QT–RR relationships and calculation of
individual-animal rate corrections. Single samples for measurement
of moxiﬂoxacin plasma concentration were collected 2.5 to 5 after
dosing for 3 sites; multiple samples were obtained from one site in
satellite animals. Full moxiﬂoxacin toxicokinetic proﬁles were not
available on the days of cardiovascular data collection because of
the impact of handling and phletobotomy on cardiovascular function.
2.1.1.3. Telemetered ECG acquisition. All dogs were instrumented with
commercial telemetry implants and allowed to recover for at least
three weeks prior to use. The implants used at sites A, B, C, and G
were model TL11M3-D70-PCTP or model TL11M2-D70-PCT (Data Sci-
ences International, St. Paul, Minnesota) and, at site E, Cardiovascular
Total Telemetry Implant, model T27F (Konigsberg Instruments Inc.,
Pasadena, California). ECG leads were positioned to approximate a
LII electrocardiogram. At sites A, B and C, ECG leads were positioned
intra-thoracically with the positive lead secured at the apex of the
heart, and the negative lead secured to the mediastinal reﬂection at
the base of the heart (site A), to the epicardial surface at the left auri-
cle of the heart (site B), or to the pericardium above the right atrium
(site C). At site E, the positive lead was sutured subcutaneously near
the apex of the heart, and the negative lead was positioned in the tho-
racic aorta. At site G, the positive ECG lead was placed in an interspace
on the left caudal–lateral thorax beneath the overlying musculature,
with the negative positioned just below the pectoral muscles against
the rib cage near the ﬁrst interspace. Telemetry transmitters were
placed in the abdominal cavity and secured to the inside of the ab-
dominal wall, or between the interior and exterior abdominal oblique
muscles.
Telemetry data were collected continuously for a 1–2 hour period
prior to dosing and until approximately 23 h after dosing. ECG
waveforms were sampled at 500 Hz and compiled at a 10 second
logging rate for sites A, B, E, and G, or collected continuously
(e.g., beat-to-beat) for site C. Acquisition systems and software in-
cluded ART™ release 4.1 (Data Sciences International, DSI, St. Paul,
Minnesota, USA) at site C, OpenART™ linked to PONEMAH P3Plus
data-analysis software releases 4.7 at site A, 4.8 at site G, and 4.9 at
site B (DSI, St. Paul, Minnesota, USA and Valley View, Ohio, USA). Sites
A and G also used ECG PRO template analysis (DSI, performance Valley
View, Ohio, USA) and post hoc ﬁltering of extraneous data using Excel®
2003 (Microsoft, Redmond, USA) or SAS (SAS Cary, North Carolina,
USA) to remove electrical or mechanical noise. Data processing at
the remaining sites used internal software developed in RPL at site C
(RS/1 programming language, RS/1 release 6.3, Applied Materials,
location), and VR2 Software at site E (Integrated Telemetry Systems,
Wilmington, Delaware, USA).
2.1.2. Cynomolgus monkey
2.1.2.1. Site A
2.1.2.1.1. Animal preparation. Cynomolgus monkeys (3 males and 3
females) weighing 3.7–6.3 kg were used in this study. A telemetry
transmitter (TL11M3-D70-PCTP; Data Sciences International) was
implanted intraperitoneally and was ﬁxed inside the abdominal
wall of each animal. The leads of the ECG were positioned
intra-thoracically with the positive lead positioned directly to the
myocardium near the apex of the heart, while the negative lead was
secured to the mediastinum. A pressure transducer was placed in
the femoral artery for systemic pressure. A second pressure transduc-
er was placed in the left ventricle. The monkeys were also implanted
with SoloPort™ subcutaneous vascular access ports (Instech Solo-
mon, 5209 Militia Hill Road, Plymouth Meeting, PA 19462). Animals
were treated with antibiotics and analgesics after surgery.
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chloride was prepared in water and the suspensions were orally ad-
ministered (0.5 mL/kg) by oral gavage. Vehicle or moxiﬂoxacin
were administered at 0, 10 and 50 mg/kg in a parallel design. All
treatments were separated by at least 1 week. All animals were fasted
overnight prior to treatment. Blood samples for measurement of
moxiﬂoxacin plasma concentration were collected 5 and 25 h after
dosing.
2.1.2.1.3. Telemetered ECG acquisition. All animals were housed in-
dividually in stainless steel cages and placed on a 12:12 h light–
dark cycle with temperature ranges of 18–29 °C, and relative humid-
ity ranges of 30–70%. All animals were given solid food once daily and
water available ad libitum. On dosing days, the food was given at ap-
proximately 4 h post-dose. Blood pressure and ECG signals were con-
tinuously recorded from 1 to 2 h before until approximately 23 h
after dosing with an OpenART™ linked to PONEMAH P3Plus data-
analysis software release 4.7 (DSI, St. Paul, Minnesota, USA and Valley
View, Ohio, USA) at 500 and 1000 Hz respectively.
2.1.2.2. Site B
2.1.2.2.1. Animal preparation. Cynomolgus monkeys (3 males and 3
females), 44–56 months of age, weighing 3.3–4.0 kg (Hamri Co., Ltd.,
Ibaraki, Japan) were used in this study. A telemetry transmitter
(TL11M2-D70-PCT; Data Sciences International) was implanted intra-
peritoneally and was ﬁxed inside the abdominal wall of each animal
under isoﬂurane anesthesia. A catheter for the measurement of
blood pressure was inserted into the femoral artery and was posi-
tioned in the abdominal aorta, and lead wires for the recording of
the electrocardiogram were sutured to the epicardial surface at the
apical end of the heart (positive electrode) and to pericardia near
the left auricle of the heart (negative electrode). Animals were treat-
ed with antibiotics and analgesics after surgery and allowed to recov-
er for at least one month before use.
2.1.2.2.2. Drug preparation and TK analysis. Moxiﬂoxacin hydro-
chloride was obtained from either Chemos GmbH (Regenstauf,
Germany) and prepared as a suspension in 0.5% methylcellulose. Sus-
pensions were orally administered (2 mL/kg for 0, 3, 10, 30 mg/kg;
5 mL/kg for 100 mg/kg) by oral gavage. Vehicle or moxiﬂoxacin
were administered at 0, 3, 10, 30, and 100 mg/kg in a cross over de-
sign. All treatments were separated by at least 1 week. All animals
were fasted overnight prior to treatment. Blood samples for measure-
ment of moxiﬂoxacin plasma concentration were collected 5 and 25 h
after dosing, and determined by a HPLC method.
2.1.2.2.3. Telemetered ECG acquisition. All animals were housed in-
dividually in stainless steel cages and placed on a 12:12 h light–
dark cycle (lighting: 7:00–19:00) with temperature ranges of 18–
28 °C, and relative humidity ranges of 35–75%. All animals were
given solid food once daily and water available ad libitum. On dos-
ing days, the food was given between 5 and 7 h post-dose. Blood
pressure and ECG signals were continuously recorded from 2 h be-
fore until 24.5 h after dosing with an OpenART™ linked to
PONEMAH P3Plus data-analysis software releases 4.9 (DSI, St.
Paul, Minnesota, USA and Valley View, Ohio, USA) at 500 and
1000 Hz respectively.
2.1.2.3. Site C
2.1.2.3.1. Animal preparation. Cynomolgus monkeys (3 males and 3
females) weighing 2.8–8.1 kg were used in this study. A telemetry
transmitter (TL11M2-D70-PCT; Data Sciences International) was im-
planted intraperitoneally and was ﬁxed inside the abdominal wall of
each animal under halothane anesthesia. A left thoracotomy was
performed between the fourth and the ﬁfth intercostal space. One
transmitter electrode was sutured directly to the left ventricular epi-
cardium near the apex while the second electrode was sutured to the
pericardium above the right atrium to approximate a limb Lead II
electrocardiogram. The body of the transmitter was placed into theperitoneal cavity and secured to the abdominal wall. Animals were
treated with antibiotics and analgesics after surgery and allowed to
recover for at least one month before use.
2.1.2.3.2. Drug preparation and TK analysis. Moxiﬂoxacin (Sigma
Aldrich, Saint Quentin, France) was administered in 0.5% as a suspen-
sion in 0.5% methylcellulose solution by the oral route in a volume of
5 ml/kg. All treatments with drugs were performed between 15:00
and 15:30. Vehicle or moxiﬂoxacin were administered at 0 and
90 mg/kg in a parallel design. All treatments were separated by at
least 1 week. All animals were fasted overnight prior to treatment.
TK analysis was not performed.
2.1.2.3.3. Telemetered ECG acquisition. All animals were housed in-
dividually in stainless steel cages and placed on a 12:12 h light–
dark cycle with temperature ranges of 20–24 °C, and relative humid-
ity ranges of 45–65%. Solid diet was given ad libitum, supplemented
with fresh vegetables, fruits, bread, and cereals. All animals were
given water available ad libitum. ECG waveforms were continuously
recorded at a sampling rate of 500 Hz using the ART acquisition soft-
ware release 4.1 (Data Sciences International, St. Paul, Minn.). Cardiac
conduction times including QT interval were calculated from a
beat-to-beat analysis using internal software developed in RPL (RS/1
programming language, RS/1 release 6.3, Applied Materials), GLP val-
idated. The percentage of error in location of the end of the T wave
was less than 3%.
2.1.2.4. Sites F and G
2.1.2.4.1. Animal preparation. Cynomolgus monkeys (7 females for
Site F and 4 males for Site G) weighing 2.9–5.2 kg were used in this
study. A telemetry transmitter (D70-PCTX; Data Sciences Internation-
al) was implanted intraperitoneally and was ﬁxed inside the abdom-
inal wall of each animal under isoﬂurane anesthesia. The red ECG
lead (positive lead) was sutured to the apex of the heart using
non-absorbable sutures and Vetbond® glue. The clear ECG lead (neg-
ative lead) was sutured to the right atrium or the mediastinal reﬂec-
tion over the atrial appendage. The quality of the ECG signal was
veriﬁed on the telemetry computer screen. Animals were treated
with antibiotics and analgesics after surgery.
2.1.2.4.2. Drug preparation and TK analysis. Moxiﬂoxacin hydro-
chloride was prepared as a suspension in 0.5% carboxymethylcellu-
lose. Suspensions were orally administered (0.5 mL/kg for 10 mg/kg;
1.5 mL/kg for 30 mg/kg; 5 mL/kg for 0 and 100 mg/kg) by oral gavage.
Vehicle or moxiﬂoxacin were administered at 0, 10, 30, and 100 mg/kg
in a cross over design. All treatmentswere separated by at least 1 week.
All animals were fasted overnight prior to treatment. TK analysis was
not performed.
2.1.2.4.3. Telemetered ECG acquisition. All animals were housed in-
dividually in stainless steel cages and placed on a 12:12 h light–
dark cycle with temperature ranges of 18–29 °C, and relative humid-
ity ranges of 30–70%. All animals were given solid food once daily and
water available ad libitum. Blood pressure and ECG signals were con-
tinuously recorded from 1 to 2 h before until approximately 23 h
after dosing with an OpenART™ linked to PONEMAH P3Plus
data-analysis software releases 4.8 (DSI, St. Paul, Minnesota, USA
and Valley View, Ohio, USA) at 500 Hz.
2.1.3. Marmoset — sites B and C
2.1.3.1. Animal preparation. Common marmosets (4 males and 4 fe-
males) weighing 291–388 g (CLEA Japan, Inc., Tokyo, Japan) for site
B and 3 males and 3 females weighing 279–350 g (Harlan UK Ltd.,
Oxfordshire, UK) for site C were used in this study. Telemetry trans-
mitters (TL11M2-C50-PXT, Data Sciences International, St. Paul, MN,
USA, both sites) were implanted in the peritoneal cavity of each ani-
mal under isoﬂurane anesthesia (0.5–3%) for site B or under ketamine
(25 mg/kg i.m.) and propofol (30 mg/kg/h infusion) for site C. ECG
electrodes were implanted subcutaneously in Lead II conﬁguration
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in the upper right of the thorax and left groin for site C. Animals were
treated with antibiotics and analgesics after surgery and allowed to
recover for at least one month before use at both sites.
2.1.3.2. Drug preparation. Moxiﬂoxacin hydrochloride was obtained
from either Chemos GmbH (Regenstauf, Germany) or Sigma Aldrich
(Saint Quentin, France) and prepared as a suspension in 0.5% meth-
ylcellulose. Suspensions were orally administered (5 mL/kg) by
oral gavage. Dosing was performed at approximately 10:00 a.m.
(site B) or 3:00 p.m. (site C). At site B vehicle or moxiﬂoxacin were
administered at 0, 10, 30, and 100 mg/kg in a Latin square design
while site C sequentially administered vehicle and thenmoxiﬂoxacin
at 0 and 90 mg/kg. All treatments were separated by at least 1 week.
All animals were fasted overnight prior to treatment. The moxiﬂoxacin
plasma values used for the current PK-QTca modeling have been previ-
ously reported. (Komatsu et al., 2010).
2.1.3.3. Telemetered ECG acquisition. All animals were housed individ-
ually in stainless steel cages and placed on a 12:12 h light–dark cycle
(lighting: 7:00–19:00 at site B or 7:30–19:30 at site C) with temper-
ature ranges of 24–31 °C (site B) and 22–26 °C (site C), and relative
humidity ranges of 35–75% (site B) and 45–65% (site C). All animals
were given solid food once daily and water available ad libitum. On
dosing days, the food was given between 5 and 7 h post-dose.
Blood pressure and ECG signals were continuously recorded from
2 h before until 24.5 h after dosing with Dataquest ART data acquisi-
tion system (Data Sciences International, ver. 4.1, St. Paul, Minn.) at
500 and 1000 Hz respectively (site B) or 500 Hz for both parameters
(site C). Recordings were performed under quiet conditions except
during scheduled periods of feeding, dosing, and cleaning of the an-
imal rooms and cages (morning period). Data were analyzed using
HEM data analysis software (Notocord Systems SAS, Croissy sur
Seine, France) for site B. Data from site C were derived from
beat-to-beat analysis using internally developed GLP-validated soft-
ware (RS/1 programming language, RS/1 release 6.3, Applied
Materials).
2.1.4. Minipig
2.1.4.1. Site F
2.1.4.1.1. Animal preparation. Six (3/sex) experimentally naïve
Gottingen minipigs, 4–5 months of age (Marshall BioResources,
North Rose, NY), weighing between 13.19 and 14.29 kg, were received
at the test facility and allowed an acclimation period of 2 weeks prior
to initiation of experimental protocols. All animals were instrumented
with Data Sciences International (DSI) D70-PCT telemetry devices,
with the pressure catheter sited within the internal iliac artery and
ECG leads conﬁgured in an intrathoracic (base-apex) epicardial lead
array (positive lead on the ventricular apex, negative lead near the
mediastinum). Minipigs were instrumented between 2 and 3 weeks
prior to placement on study, and were administered appropriate
post-surgical regimens of antibiotics and analgesics to facilitate
recovery.
2.1.4.1.2. Drug preparation and PK analysis. Moxiﬂoxacin hydro-
chloride (The Harvard Group, Livonia, MI, USA) was received in tablet
form and ground for suspension in the vehicle, 0.5% methylcellulose
(Spectrum Chemicals, Gardena, CA, USA) in distilled water. Fresh sus-
pensions were prepared on each day of dosing at 5, 15, and 50 mg/mL
to achieve dose administrations of 10, 30, and 100 mg/kg at a dose
volume of 2 mL/kg. Dose formulations were stirred during dose
administration to ensure uniformity, and, beginning with the vehicle,
administered in ascending order with a 7-day washout period be-
tween each successive dose. During a separate, subsequent study
phase, blood samples for PK analysis were collected prior to dosingand at 15, 30, 60, 120, 240, and 480 min, and 24 h post-dose for
moxiﬂoxacin using a LC–MS/MS method.
2.1.4.1.3. Telemetered ECG acquisition. Animals were singly housed
within stainless steel caging in an AAALAC accredited laboratory envi-
ronment on a 12:12 light–dark cycle (lights on at 06:00 h), and were
maintained on a certiﬁed minipig diet with discrete twice daily feed-
ings between 06:00 h and 07:00 h and 14:00 h and 15:00 h. Water
was available ad libitum. Temperature and humidity were monitored
and recorded daily and maintained between 69 and 81 °F and be-
tween 30 and 70%, respectively. Cages were enriched with a variety
of designated toys and manipulanda. ECG and blood pressure wave-
forms were digitized at 250 and 500 Hz, respectively, and analyzed
with P3 (Ponemah Physiology Platform, V4.9, Data Sciences Interna-
tional, St. Paul, Minn.). All parameters were acquired continuously
at a system default logging rate of 10 s for 2 h prior to and for 24 h
after dose administrations.
2.1.4.2. Site E
2.1.4.2.1. Animal preparation. Six female minipigs (age 14 months,
weight 18.0 to 23.0 kg, Ellegaard, DK) were instrumented with
T27G-11-TK-Y11 implants (ITS, Lakeville, PA) where the arterial
blood pressure transducer measurement was placed in the thoracic
aorta and also served as the positive ECG lead. The reference electrode
was placed subcutaneously near the apex of the heart in an approxi-
mate Lead II conﬁguration. Animals were treated with analgesics and
antibiotics for at least 5 days. Telemetric transmitters were implanted
at least 21 days before use of the animals.
2.1.4.2.2. Drug preparation and PK analysis. Moxiﬂoxacin hydro-
chloride salt (Chemie Brunschwig AG, Switzerland) was dissolved in
demineralized water and administered by oral gavage at doses of
10, 30, and 100 mg/kg in a dosing volume of 6 ml/kg at concentra-
tions of 1.8, 5.5 and 18.2 mg/ml moxiﬂoxacin HCl. Animals were
dosed in a modiﬁed Latin square design with 96 h washout between
dosing days. Blood samples for PK analysis were taken on all days at 0,
4, and 24 h post dose and analyzed for moxiﬂoxacin with a LC–MS/
MS method.
2.1.4.2.3. Telemetered ECG acquisition. When not on study, animals
were pair-housed in stalls under controlled temperature (18 °C ±
2 °C) and humidity (40 to 80%). Animals were single-housed on
study days. Enrichment was provided with plastic beads, straw bed-
ding, and toys. Background music was played during the 12 h light
cycle. Animals had continuous access to water and were fed with a
commercial diet (Provimi, Kliba, No 3000 (pellets), supplemented
by hay (Provimi Kliba No 4645) at predose and at 4 h post dose.
ECG and blood pressure waveforms were digitized at 250 and
500 Hz, respectively, and analyzed with Ponemah software, ver.
5.00 (Data Sciences International, St. Paul Minn.). All parameters
were acquired continuously at a default logging rate of 10 s for 1–
2 h prior to and for 20 h after dosing.
2.1.5. Guinea pig
2.1.5.1. Site C
2.1.5.1.1. Animal preparation. Five (3 males and 2 females) Hartley
guinea pigs (Charles River, France) weighing 570–1090 g on the day
of dosing were used in this study. Telemetry transmitters (TL11M2-
C50-PXT, Data Sciences International, St. Paul, MN, USA) were im-
planted in the peritoneal cavity under metedomidine (0.03 mg/kg,
i.m.) and ketamine (40 mg/kg, i.m.) anesthesia. The ECG electrodes
were implanted subcutaneously in Lead II conﬁguration in the
upper part of the right side of the thorax versus left groin. The animals
were treated with meloxicam (0.5 mg/kg, p.o.) for three days after
the surgery and were allowed to recover from the surgery for at
least one month before dosing.
2.1.5.1.2. Drug preparation and PK analysis. Moxiﬂoxacin hydro-
chloride (moxiﬂoxacin) was obtained from Sigma Aldrich (Saint
Table B
Site Value Std Error DF t value p value
A −0.177 0.231 24 −0.766 0.451
C −0.050 0.231 24 −0.216 0.831
B −0.011 0.116 24 −0.096 0.924
G 0.110 0.163 24 0.675 0.506
F 0.014 0.124 24 0.117 0.908
Table C
Site Value Std error DF t-value Lower Upper
I-B 0.0412 0.3310 37 0.1245 −0.6295 0.7119
I-G 0.3143 0.4484 14 0.7009 −0.6474 1.2759
I-F 0.4875 0.3389 14 1.4382 −0.2395 1.2144
S-B 0.0168 0.0034 37 4.9111 0.0099 0.0237
S-G 0.0195 0.0048 37 4.0590 0.0098 0.0293
S-F 0.0088 0.0036 37 2.4257 0.0015 0.0162
S maxDiff 0.0107 0.0060 37 1.7752 −0.0015 0.0229
Table D
Canine subjects (n) by dose.
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moxiﬂoxacin at 90 mg/kg. Moxiﬂoxacin was prepared as a suspension
in 0.5% methylcellulose solution and 1 mL/kg of the suspension was
orally administered to the animals by gastric gavage. Dosing was
performed at 15:00 to minimize environmental disturbances during
telemetry recordings. The animals were fasted overnight before test
article administration.
In a separate study and animals, moxiﬂoxacin in 0.5% methylcel-
lulose was administered by oral gavage at 90 mg/kg for plasma drug
analysis. Three blood samples (0.2 ml/sample) were withdrawn
from the jugular vein per animal at three randomly distributed post
dose timepoints: 0, 1, 2, 4, 6, 8, and 24 h post-dose. The blood was
collected into Li-heparin tubes and plasma was obtained from the
blood by centrifugation at 1500 ×g for 10 min at 4 °C. The plasma
samples were stored frozen at −70 °C until determination of the
plasma concentrations of moxiﬂoxacin using a LC–MS method.
2.1.5.1.3. Telemetered ECG acquisition. All animals were housed in-
dividually in cages of standard dimensions with sawdust bedding
and placed in an animal room on a 12:12 h light–dark cycle (lighting
7:30–19:30) with a temperature range of 20–24 °C and a relative hu-
midity range of 45–65%. The animals were given solid food and water
ad libitum. ECG signals were continuously recorded with a Dataquest
ART data acquisition system (Data Sciences International, release 4.1)
at a 500 Hz sampling rate from 2 h before until 24.5 h after dosing.
The recordings were performed under quiet conditions except during
scheduled periods of feeding, dosing and cleaning of the animal
rooms (morning period). Data were calculated from a beat-to-beat
analysis using an internal software developed in RPL (RS/1 program-
ming language, RS/1 release 6.3, Applied Materials), GLP validated.
The percentage of errors in location of the end of the T wave was
less than 5% in guinea pigs.
2.2. Statistical analyses
2.2.1. Investigation of center effect for QTca AUC in percent
The investigation was performed for dog, cyno and minipig, for
which sufﬁcient data were available.
2.2.1.1. Cynomolgus monkey.Table A
Cynomolgus monkey subjects (n) by dose.
Site Cynomolgus dose (mg/kg)
3 10 30 90 100
A 0 6 0 0 0
C 0 0 0 6 0
B 6 6 6 0 6
G 0 4 4 0 4
F 0 7 7 0 7
Site Canine dose (mg/kg)
3 10 30 90
A 0 8 8 0
C 0 0 0 6
B 6 6 6 0
G 0 8 8 8
E 6 6 6 0
Table E
Value Std error DF t value p value
Intercept 0.2505 0.0997 47 2.5118 0.0155
Dose 0.0316 0.0018 47 17.4906 0.0000Two centers, A and C, dosed their animals only once with 10 and
90 mg respectively. Therefore, a common analysis of variance taking
into account dose cannot be preformed. Instead, a common dose-
dependency was estimated in a ﬁrst regression step, and the residuals
from this analysis were then subjected to a second analysis of vari-
ance taking into account the site as only ﬁxed effect.
The results from the ﬁrst analysis are summarized below:Value Std error DF t value p value
Intercept 0.1610 0.1660 39 0.965 0.34
Dose 0.0148 0.0021 39 7.080 b0.0001The analysis of variance then gives the following center effects:This analysis does not point to any sizeable center effect.
Alternatively, the two centers that did not give multiple doses can
be excluded from the analysis. The key results of this analysis are
given below as t-values with 95% conﬁdence intervals. For all centers,
the intercept (“I”) is not signiﬁcantly different from zero and the
slope (“S”) is between 0.01 and 0.02 (% per mg dose). The conﬁdence
interval between the smallest and the largest slope (last row of the
table below) contains zero. In other words, this analysis, too, gives
no hint for a center effect.2.2.1.2. Dog. The number of animals per site and dose is given below:Since, again, C contributes only to one dose, a two stage analysis as
performed for the cynomolgus monkey is worth trying.
The results of the regression analysis on dose are given below:It should be noted that the intercept is relatively high, which may
be an indication that a linear dose–response model is not fully ade-
quate. However, this is explored further in this context.
98 H. Holzgrefe et al. / Journal of Pharmacological and Toxicological Methods 69 (2014) 61–101The results of the ANOVA—second step—are given below:Table F
Site Value Std error DF t value p value
A −0.077 0.084 29 −0.914 0.368
C −0.195 0.137 29 −1.426 0.165
B 0.148 0.079 29 1.872 0.071
G −0.008 0.068 29 −0.115 0.909
E −0.004 0.079 29 −0.055 0.957
Table I
Value Std error DF t value p value
Intercept: dose 10 0.4125 0.2399 20 1.7197 0.1009
Dose: 30 vs. 10 0.6143 0.2764 20 2.2223 0.0380
Dose: 100 vs. 10 1.8868 0.2764 20 6.8254 0.0000
Site 0.0365 0.3392 10 0.1076 0.9164
Interaction site: dose 30 −0.4040 0.3910 20 −1.0334 0.3138
Interaction site: dose 100 0.0495 0.3910 20 0.1266 0.9005
Table J
Relative center effects across species: QTca percentage AUC.
Species DF numerator DF denominator F p
Dog 4 29 24.73 0.000
Cyno 1 11 0.00 0.963
Minipig 1 10 0.10 0.754Overall, there is no strong sign for a center effect. The numerically
large value for C must be seen in the context of the small number of
measurements at this center, which is expressed by the large stan-
dard error and, as a consequence, a p-value well above 0.1. There is
some indication that B may be somewhat different, but if multiplicity
is taken into account, this is far from being evident.
An alternative analysis is to use a model with dose and site as fac-
tors (but no interaction). Looking at the deviations of each center
from the common unweighted mean gives the results below. Now,
the deviation of center B from the rest of the data becomes more ev-
ident—the full 95% conﬁdence interval is above zero.Table G
Deviations of each center from the common unweighted mean (dog). The deviation of
center B from the rest of the data becomes more evident—the full 95% conﬁdence inter-
val is above zero.
Center Deviation SE DF t value Conﬁdence
interval
Lower Upper
C −0.41 0.20 29 −2.02 −0.82 0.01
A −0.25 0.13 29 −1.83 −0.52 0.03
G −0.06 0.12 29 −0.50 −0.31 0.19
E 0.07 0.14 29 0.51 −0.22 0.36
B 0.64 0.14 29 4.53 0.35 0.93
Table K
DF Sum sq Mean sq F value P (>F)
Origin 1 0.22165 0.221647 12.9901 0.00108
BW 1 0.07936 0.079361 4.6512 0.03890
Sponsor 3 0.14007 0.046691 2.7364 0.06028
Residuals 31 0.52894 0.017063
Table L
The analysis of the cyno beta data reveals that the main inhomogeneity can be
explained by the origin (p = 0.001), body weight seems to play a marginal role and
the center effect is still present, but rather small (p = 0.06). The latter is probably
mainly due to a difference between the two centers using Mauritius cynos.
Df Sum sq Mean sq F value P (>F)Gender and body weight were also incorporated in this analysis,
but these variables did not signiﬁcantly contribute to the variability
seen and did not explain the Site effect.
2.2.1.3. Minipig. There are only two centers contributing, but these use
the same doses and same number of animals. Therefore, the standard
analysis with either dose as a factor or as a covariate is directly
applicable.
An analysis with a model using dose as a continuous covariate
gives these results:Table H
Value Std error DF t value p value
Intercept 0.3018 0.2240 22 1.3477 0.1915
Dose 0.0202 0.0029 22 7.0208 b0.001
Site −0.1796 0.3167 10 −0.5670 0.5832
Interaction 0.0021 0.0041 22 0.5148 0.6118
Origin 1 0.22165 0.221647 12.9901 0.001082
BW 1 0.07936 0.079361 4.6512 0.038903
Origin:Sponsor 3 0.14007 0.046691 2.7364 0.060282
Residuals 31 0.52894There is clear dose dependence, but no indication for a difference
between the two sites. Note that also the intercept is not signiﬁcant,
which supports the use of a linear model.The model using dose as factor also does not give any indication
for a site difference:In summary, with the data at hand, there is no indication for a site
difference in the minipig.ANOVA with site and dose as factors, random subject effect
The analysis of the cyno beta data reveals quite nice results: The
main in-homogeneity can be explained by the origin (p = 0.001).
Body weight seems to play a marginal role and the center effect is
still present, but rather small (p = 0.06). It is probably mainly due to
a difference between the two centers using Mauritius cynos. Here is
the analysis of variance table:2.2.2. Investigation of cynomolgus monkey source effect on beta valueReferences
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